A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
Tumors or cancers of the KIDNEY.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
Excision of kidney.
Tumors or cancer of the LIVER.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.
A ubiquitin-protein ligase that mediates OXYGEN-dependent polyubiquitination of HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT. It is inactivated in VON HIPPEL-LINDAU SYNDROME.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
A cell line derived from cultured tumor cells.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Organic salts and esters of benzenesulfonic acid.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Compounds that include the amino-N-phenylamide structure.
Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
A malignant epithelial tumor with a glandular organization.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Tumors or cancer of the LUNG.
Tumors or cancer of the THYROID GLAND.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Tumors or cancer of the human BREAST.
Tumors or cancer of the NASOPHARYNX.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
An autosomal dominant disorder caused by mutations in a tumor suppressor gene. This syndrome is characterized by abnormal growth of small blood vessels leading to a host of neoplasms. They include HEMANGIOBLASTOMA in the RETINA; CEREBELLUM; and SPINAL CORD; PHEOCHROMOCYTOMA; pancreatic tumors; and renal cell carcinoma (see CARCINOMA, RENAL CELL). Common clinical signs include HYPERTENSION and neurological dysfunctions.
DNA present in neoplastic tissue.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.
Tumors or cancer of the ESOPHAGUS.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Tumors or cancer of the MOUTH.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer of the SKIN.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Tumors or cancer of the URINARY BLADDER.
Tumors or cancer of the COLON.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
The state of having multiple leiomyomas throughout the body. (Stedman, 25th ed)
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Tumors or cancer of the STOMACH.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
Elements of limited time intervals, contributing to particular results or situations.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
An enzyme that catalyzes the reversible hydration of fumaric acid to yield L-malic acid. It is one of the citric acid cycle enzymes. EC 4.2.1.2.
Tumors or cancer of the UTERINE CERVIX.
Antibodies produced by a single clone of cells.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
RNA present in neoplastic tissue.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Tumors or cancer of the gallbladder.
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
A heterogeneous group of hereditary and acquired disorders in which the KIDNEY contains one or more CYSTS unilaterally or bilaterally (KIDNEY, CYSTIC).
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Transplantation between animals of different species.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.
The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.
Tumors or cancer of the TONGUE.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
Established cell cultures that have the potential to propagate indefinitely.
A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Tumors or cancer of the BRONCHI.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
Tumors or cancer of the SALIVARY GLANDS.
Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Agents that inhibit PROTEIN KINASES.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.
A family of zinc-containing enzymes that catalyze the reversible hydration of carbon dioxide. They play an important role in the transport of CARBON DIOXIDE from the tissues to the LUNG. EC 4.2.1.1.
The renal tubule portion that extends from the BOWMAN CAPSULE in the KIDNEY CORTEX into the KIDNEY MEDULLA. The proximal tubule consists of a convoluted proximal segment in the cortex, and a distal straight segment descending into the medulla where it forms the U-shaped LOOP OF HENLE.
Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Tumors or cancer of the URINARY TRACT in either the male or the female.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Tumors or cancers of the ADRENAL CORTEX.
Tumors or cancer located in bone tissue or specific BONES.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
Biochemical identification of mutational changes in a nucleotide sequence.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
Proteins prepared by recombinant DNA technology.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Hypoxia-inducible factor 1, alpha subunit is a basic helix-loop-helix transcription factor that is regulated by OXYGEN availability and is targeted for degradation by VHL TUMOR SUPPRESSOR PROTEIN.
Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
The epithelial lining of the URINARY TRACT.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
Long convoluted tubules in the nephrons. They collect filtrate from blood passing through the KIDNEY GLOMERULUS and process this filtrate into URINE. Each renal tubule consists of a BOWMAN CAPSULE; PROXIMAL KIDNEY TUBULE; LOOP OF HENLE; DISTAL KIDNEY TUBULE; and KIDNEY COLLECTING DUCT leading to the central cavity of the kidney (KIDNEY PELVIS) that connects to the URETER.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A benign tumor containing vascular, adipose, and muscle elements. It occurs most often in the kidney with smooth muscle elements (angiolipoleiomyoma) in association with tuberous sclerosis. (Dorland, 27th ed)
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
A skin carcinoma that histologically exhibits both basal and squamous elements. (From Dorland, 27th ed)
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
Short sequences (generally about 10 base pairs) of DNA that are complementary to sequences of messenger RNA and allow reverse transcriptases to start copying the adjacent sequences of mRNA. Primers are used extensively in genetic and molecular biology techniques.
Surgical removal of the thyroid gland. (Dorland, 28th ed)
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.
Chemotherapy-induced dermal side effects that are associated with the use of various CYTOSTATIC AGENTS. Symptoms range from mild ERYTHEMA and/or PARESTHESIA to severe ulcerative dermatitis with debilitating pain involving typically palmoplantar and intertriginous areas. These cutaneous manifestations are sometimes accompanied by nail anomalies.
Tumors or cancer of the UTERUS.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.

Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. (1/3818)

Par-4 is a widely expressed leucine zipper protein that confers sensitization to apoptosis induced by exogenous insults. Because the expression of genes that promote apoptosis may be down-regulated during tumorigenesis, we sought to examine the expression of Par-4 in human tumors. We present here evidence that Par-4 protein levels were severely decreased in human renal cell carcinoma specimens relative to normal tubular cells. Replenishment of Par-4 protein levels in renal cell carcinoma cell lines conferred sensitivity to apoptosis. Because apoptosis may serve as a defense mechanism against malignant transformation or progression, decreased expression of Par-4 may contribute to the pathophysiology of renal cell carcinoma.  (+info)

Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. (2/3818)

Dihydropyrimidine dehydrogenase (DPD) is responsible for the breakdown of the widely used antineoplastic agent 5-fluorouracil (5FU), thereby limiting the efficacy of the therapy. To identify patients suffering from a complete or partial DPD deficiency, the activity of DPD is usually determined in peripheral blood mononuclear cells (PBM cells). In this study, we demonstrated that the highest activity of DPD was found in monocytes followed by that of lymphocytes, granulocytes and platelets, whereas no significant activity of DPD could be detected in erythrocytes. The activity of DPD in PBM cells proved to be intermediate compared with the DPD activity observed in monocytes and lymphocytes. The mean percentage of monocytes in the PBM cells obtained from cancer patients proved to be significantly higher than that observed in PBM cells obtained from healthy volunteers. Moreover, a profound positive correlation was observed between the DPD activity of PBM cells and the percentage of monocytes, thus introducing a large inter- and intrapatient variability in the activity of DPD and hindering the detection of patients with a partial DPD deficiency.  (+info)

Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. (3/3818)

The clinical impact of dendritic cells (DCs) in the treatment of human cancer depends on their unique role as the most potent antigen-presenting cells that are capable of priming an antitumor T-cell response. Here, we demonstrate that functional DCs can be generated from peripheral blood of patients with metastatic renal cell carcinoma (RCC) by culture of monocytes/macrophages (CD14+) in autologous serum containing medium (RPMI) in the presence of granulocyte macrophage colony-stimulating factor and interleukin (IL) 4. For testing the capability of RCC-antigen uptake and processing, we loaded these DCs with autologous tumor lysate (TuLy) using liposomes, after which cytometric analysis of the DCs revealed a markedly increased expression of HLA class I antigen and a persistent high expression of class II. The immunogenicity of DC-TuLy was further tested in cultures of renal tumor infiltrating lymphocytes (TILs) cultured in low-dose IL-2 (20 Biologic Response Modifier Program units/ml). A synergistic effect of DC-TuLy and IL-2 in stimulating a T cell-dependent immune response was demonstrated by: (a) the increase of growth expansion of TILs (9.4-14.3-fold; day 21); (b) the up-regulation of the CD3+ CD56- TcR+ (both CD4+ and CD8+) cell population; (c) the augmentation of T cell-restricted autologous tumor lysis; and (d) the enhancement of IFN-gamma, tumor necrosis factor-alpha, granulocyte macrophage colony-stimulating factor, and IL-6 mRNA expression by TILs. Taken together, these data implicate that DC-TuLy can activate immunosuppressed TIL via an induction of enhanced antitumor CTL responses associated with production of Thl cells. This indicates a potential role of DC-TuLy vaccines for induction of active immunity in patients with advanced RCC.  (+info)

Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. (4/3818)

PURPOSE: Sarcomatoid variants of renal cell carcinoma (RCC) are aggressive tumors that respond poorly to immunotherapy. We report the outcomes of 31 patients with sarcomatoid RCC treated with a combination of surgical resection and immunotherapy. PATIENTS AND METHODS: Patients were identified from the database of the University of California Los Angeles Kidney Cancer Program. We retrospectively reviewed the cases of 31 consecutive patients in whom sarcomatoid RCC was diagnosed between 1990 and 1997. Clinical stage, sites of metastasis, pathologic stage, and type of immunotherapy were abstracted from the medical records. The primary end point analyzed was overall survival, and a multivariate analysis was performed to distinguish any factors conferring an improved survivorship. RESULTS: Twenty-six percent of patients were male and 74% were female, and the median age was 59 years (range, 34 to 73 years). Length of follow-up ranged from 2 to 77 months (mean, 21.4 months). Twenty-eight patients (84%) had known metastases at the time of radical nephrectomy (67% had lung metastases and 40% had bone, 21% had liver, 33% had lymphatic, and 15% had brain metastases). Twenty-five patients (81%) received immunotherapy, including low-dose interleukin (IL)-2-based therapy (five patients), tumor-infiltrating lymphocyte-based therapy plus IL-2 (nine patients), high-dose IL-2-based therapy (nine patients), dendritic cell vaccine-based therapy (one patient), and interferon alpha-based therapy alone (one patient). Two patients (6%) achieved complete responses (median duration, 46+ months) and five patients (15%) achieved partial responses (median duration, 36 months). One- and 2-year overall survival rates were 48% and 37%, respectively. Using a multivariate analysis, age, sex, and percentage of sarcomatoid tumor (< or >50%) did not significantly correlate with survival. Improved survival was found in patients receiving high-dose IL-2 therapy compared with patients treated with surgery alone or any other form of immunotherapy (P = .025). Adjusting for age, sex, and percentage of sarcomatoid tumor, the relative risk of death was 10.4 times higher in patients not receiving high-dose IL-2 therapy. Final pathologic T stage did not correlate significantly with outcome, but node-positive patients had a higher death rate per year of follow-up than did the rest of the population (1.26 v 0.76, Cox regression analysis). CONCLUSION: Surgical resection and high-dose IL-2-based immunotherapy may play a role in the treatment of sarcomatoid RCCs in select patients.  (+info)

Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. (5/3818)

PURPOSE: In patients undergoing cytokine therapy, systemically applied interleukin-2 (IL-2) and/or interferon-alpha (IFN-alpha) have been reported to induce thyroid dysfunction as well as thyroid autoantibodies. We analyzed the correlation of thyroid autoimmunity with HLA phenotype, various other autoimmune parameters, and patient survival. PATIENTS AND METHODS: For this purpose, antithyroglobulin autoantibodies, antimicrosomal thyroid autoantibodies, thyroglobulin receptor autoantibodies, thyroid dysfunction, and multiple clinical parameters were determined in 329 unselected patients with metastatic renal cell cancer before and after systemic IL-2 and IFN-alpha2 therapy. For statistical analysis, we used both univariate and multivariate Cox proportional hazards models and the two-tailed Fisher's exact test. RESULTS: Antithyroglobulin autoantibodies and antimicrosomal thyroid autoantibodies were detected in 60 patients (18%); positive autoantibody titers of various other autoimmune parameters were statistically unrelated. The presence of thyroid autoantibodies was correlated with prolonged survival (P<.0001). There was a statistically significant difference in frequencies of HLA-Cw7 expression between thyroid autoantibody-positive and -negative patients (P< or =.05), and the Cw7 expression was associated with prolonged overall survival (P = .009). CONCLUSION: The evaluation of thyroid autoantibodies during cytokine therapy could be a useful prognostic marker for patients with renal cell carcinoma who benefit from cytokine treatment. IL-2- and IFN-alpha2-induced tumor control and prolonged survival may require breaking of immunologic tolerance against self-antigens.  (+info)

Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. (6/3818)

To investigate whether diuretic medication use increases risk of renal cell carcinoma (RCC), the authors conducted a case-control study of health maintenance organization members in western Washington State. Cases (n = 238) diagnosed between January 1980 and June 1995 were compared with controls (n = 616) selected from health maintenance organization membership files. The computerized health maintenance organization pharmacy database provided information on medications prescribed after March 1977. Additional exposure information was collected from medical records. For women, use of diuretics was associated with increased risk of RCC (odds ratio (OR) = 1.8, 95% confidence interval (CI) 1.0-3.1), but the association was not independent of a diagnosis of hypertension (adjusted for hypertension, OR = 1.1, 95% CI 0.5-2.1). Similarly, nondiuretic antihypertensive use was associated with increased risk, but only when unadjusted for hypertension. For men, neither diuretic nor nondiuretic antihypertensive use was associated with risk of RCC. A diagnosis of hypertension was clearly associated with RCC risk for women (OR = 2.5, 95% CI 1.2-5.1), but not men (OR = 1.3, 95% CI 0.7-2.5). High systolic and diastolic blood pressures were associated with increased risk in both sexes. These results do not support the hypothesis that use of diuretic medication increases RCC risk; they are more consistent with an association between RCC and high blood pressure.  (+info)

Increased renal retention of 99mTc-methylene diphosphonate after nephron-sparing surgery. (7/3818)

Nephron-sparing surgery has become established as an effective treatment for localized renal cell carcinoma when preservation of renal function is necessary. The surgery usually requires temporary renal artery occlusion and may induce ischemic renal damage. In this study, we retrospectively evaluated renal activity on bone scintigraphy after nephron-sparing surgery. METHODS: Eleven patients who underwent nephron-sparing surgery for renal cell carcinoma and had a normal contralateral kidney were studied. A total of 12 bone scintigraphy images with 99mTc-labeled methylene diphosphonate were obtained within 1 y after surgery in these patients to assess skeletal metastasis. Activity in the spared renal parenchyma was compared visually with that in the contralateral normal kidney. RESULTS: The tumor was successfully resected in every patient, and no clinically significant complications occurred. Activity in the spared renal parenchyma was elevated in six of seven examinations performed within 21 d after surgery. In three examinations, the increase in renal activity was heterogeneous, being relatively prominent near the surgical margin. Increased renal activity was not observed on five examinations performed 3 mo or more after surgery. CONCLUSION: Renal retention of bone-seeking agents is elevated in the early period after nephron-sparing surgery, probably as a result of ischemic insult during the surgical procedure. Bone scintigraphy may aid in evaluating the presence and degree of ischemic damage of the spared renal parenchyma.  (+info)

Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. (8/3818)

Germ-line mutations of the human TSC2 tumor suppressor gene cause tuberous sclerosis (TSC), a disease characterized by the development of hamartomas in various organs. In the Eker rat, however, a germ-line Tsc2 mutation gives rise to renal cell carcinomas with a complete penetrance. The molecular mechanism for this phenotypic difference between man and rat is currently unknown, and the physiological function of the TSC2/Tsc2 product (tuberin) is not fully understood. To investigate these unsolved problems, we have generated a Tsc2 mutant mouse. Tsc2 heterozygous mutant (Tsc2+/-) mice developed renal carcinomas with a complete penetrance, as seen in the Eker rat, but not the angiomyolipomas characteristic of human TSC, confirming the existence of a species-specific mechanism of tumorigenesis caused by tuberin deficiency. Unexpectedly, approximately 80% of Tsc2+/- mice also developed hepatic hemangiomas that are not observed in either TSC or the Eker rat. Tsc2 homozygous (Tsc2-/-) mutants died around embryonic day 10.5, indicating an essential function for tuberin in mouse embryonic development. Some Tsc2-/- embryos exhibited an unclosed neural tube and/or thickened myocardium. The latter is associated with increased cell density that may be a reflection of loss of a growth-suppressive function of tuberin. The mouse strain described here should provide a valuable experimental model to analyze the function of tuberin and its association with tumorigenesis.  (+info)

TY - JOUR. T1 - Sclerotic bone metastases from sarcomatoid renal cell carcinoma. AU - Liu, Patrick T.. AU - Conley, Christopher R.. AU - Callstrom, Matthew R.. PY - 1999/10/1. Y1 - 1999/10/1. N2 - We present a case of sarcomatoid renal cell carcinoma with multiple sclerotic skeletal metastatic lesions. Renal cell carcinoma is frequently metastatic at presentation, with a high incidence of skeletal involvement, classically described as osteolytic. However, sclerotic or osteoblastic metastatic skeletal lesions from renal cell carcinoma are rare, with only two previous reports identified in the literature, neither of which involved the sarcomatoid variant of renal cell carcinoma. In our case the sclerotic metastases were characterized by bone scan, computed tomography (CT), magnetic resonance imaging (MRI), and histologic analysis.. AB - We present a case of sarcomatoid renal cell carcinoma with multiple sclerotic skeletal metastatic lesions. Renal cell carcinoma is frequently metastatic at ...
NOTOC__ For patient information click [[{{PAGENAME}} (patient information),here]] {{Renal cell carcinoma}} {{CMG}}; {{AE}} {{YD}}, {{SSK}}, {{SC}} {{SK}} RCC; Renal cell CA; Kidney cancer; Kidney carcinoma; Kidney CA; Grawitz tumor; Hypernephroma ==[[Renal cell carcinoma overview,Overview]]== ==[[Renal cell carcinoma historical perspective,Historical Perspective]]== ==[[Renal cell carcinoma classification,Classification]]== ==[[Renal cell carcinoma pathophysiology,Pathophysiology]]== ==[[Renal cell carcioma causes,Causes]]== ==[[Renal cell carcinoma differential diagnosis,Differentiating Renal cell carcinoma from other Diseases]]== ==[[Renal cell carcinoma epidemiology and demographics,Epidemiology and Demographics]]== ==[[Renal cell carcinoma risk factors,Risk Factors]]== ==[[Renal cell carcinoma screening,Screening]]== ==[[Renal cell carcinoma natural history, complications, and prognosis,Natural History, Complications and Prognosis]]== ==Diagnosis== [[Renal cell carcinoma ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Metastatic Renal Cell Carcinoma market report covers research informatics related to Metastatic Renal Cell Carcinoma clinical trials, such as a listing of industry and sponsored clinical trials as well as new drug therapies.. Designed to be a resource both for patients interested in participating in Metastatic Renal Cell Carcinoma clinical trials and for research professionals.. The report, Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016″ provides an overview of Metastatic Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.. Browse ...
TY - JOUR. T1 - Vagina as a rare location of renal cell carcinoma metastasis. AU - Ladjevic, I. L.. AU - Stefanovic, A.. AU - Kadija, S.. AU - Terzic, M.. AU - Jeremic, K.. AU - Janjic, T.. PY - 2016/1/1. Y1 - 2016/1/1. N2 - Introduction: Metastatic renal cell carcinoma is often found in distant organs, including lung, bone, brain,and liver. Metastases to the vagina are extremely rare. Case Report: The authors present a case of renal cell carcinoma metastasis to the anterior vaginal wall four months after nephrectomy in a 56-year-old patient. The vaginal lesions were excised. After two years the patient had no signs of recurrence or the disease progression. Conclusion: Vaginal metastases should be considered in differential diagnosis of female renal cell carcinoma patients presenting with vaginal bleeding of mass.. AB - Introduction: Metastatic renal cell carcinoma is often found in distant organs, including lung, bone, brain,and liver. Metastases to the vagina are extremely rare. Case Report: ...
PURPOSE: Careful selection is critical to identify those with metastatic renal cell carcinoma who are most likely to benefit from cytoreductive nephrectomy. Surgery in patients who have metastatic renal cell carcinoma with tumor thrombus is complex and may not benefit some patients with poor overall survival. We evaluated whether preoperative variables or risk stratification systems could predict overall survival following cytoreductive nephrectomy.. MATERIALS AND METHODS: Prognostic factors for overall survival after surgery were evaluated in patients who had metastatic renal cell carcinoma with venous tumor thrombus at 5 institutions from 2000 to 2014. Prognostic variables, including metastatic renal cell carcinoma risk models, were evaluated for associations with overall survival. Multivariable analysis was used to determine independent associations of preoperative variables with overall survival.. RESULTS: A total of 427 patients with metastatic renal cell carcinoma were identified with ...
List of Tables. Table 1: Clinical subtypes of Indication. Table 2: Risk Factors. Table 3: Prevalence cases (%) Region wise. Table 4: Sources used for forecasting the data. Table 5: Renal cell carcinoma Global Epidemiology, (2013-2023). Table 6: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), US (2013-2023). Table 7: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), US (2013-2023). Table 8: Prevalent Cases By Renal cell carcinoma Sub-population, US (2013-2023). Table 9: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), United Kingdom (2013-2023). Table 10: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), United Kingdom (2013-2023). Table 11: Prevalent Cases By Renal cell carcinoma Sub-population, United Kingdom (2013-2023). Table 12: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), Germany (2013-2023). Table 13: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), Germany (2013-2023). Table 14: Prevalent Cases By Renal cell ...
Title:Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). VOLUME: 8 ISSUE: 3. Author(s):Zofia F. Bielecka, Anna M. Czarnecka, Wojciech Solarek, Anna Kornakiewicz and Cezary Szczylik. Affiliation:Laboratory of Molecular Oncology, Department of Oncology, Military Institute of Medicine in Warsaw, Szaserów 128, 04-141 Warsaw, Poland.. Keywords:Acquired drug resistance, tyrosine kinase inhibitors, sunitinib, sorafenib, pazopanib, axitinib, tivozanib, epithelialmesenchymal transition, angiogenic switch, anti-angiogenic therapy, clear-cell renal cell carcinoma, non-genetic resistance mechanisms.. Abstract:Clear - cell renal cell carcinoma (ccRCC) is a histological subtype of renal cell carcinoma - the most prevalent adult kidney cancer. Causes of ccRCC are not completely understood and therefore number of available therapies is limited. As a consequence of tumor chemo- and radioresistance as well as restrictions in offered targeted therapies, ...
Sumanta Pal, MD of City of Hope, Duarte, CA, discusses the introduction of new data of the new single-agent cabozantinib for advanced renal cell carcinoma. The agent is a dual MET and VEGFR2 inhibitor, and has been assessed in metastatic renal cell carcinoma and other diseases. Dr Pal highlights his involvement in the Phase I trials of cabozantinibs development in renal cell carcinoma, where impressive responses were observed. He proceeds to highlight that most recently, cabozantinib was used in a Phase III METEOR trial comparing it to the agent everolimus (NCT01865747). This study identified an improvement in response rate, overall survival (OS) and progression-free survival (PFS) for patients with advanced renal cell carcinoma. According to Dr Pal, these findings make the agent the optimal second-line choice in patients with metastatic renal cell carcinoma. He further adds that data from the CABOSUN study (NCT01835158), a clinical trial that compared sunitinib and cabozantinib in the front-line
TY - JOUR. T1 - In search of a better crystal ball. T2 - Recent advances in prognostic markers for clear-cell renal cell carcinoma. AU - Shah, Jay B.. AU - Margulis, Vitaly. PY - 2010/6. Y1 - 2010/6. N2 - Advances in imaging have led to a steady increase in the incidence of kidney cancer over the last two decades. There has been no corresponding improvement in our ability to predict the behavior of renal cell carcinoma. Patients with low-risk renal cell carcinoma have good long-term survival with only localized therapy but patients with aggressive disease do poorly, even with optimal multimodal treatment. Biomarkers to differentiate between these two very divergent populations have traditionally been of only limited utility. We review the recent advances in the development of molecular and immunologic markers aimed at improving prognostication of renal cell carcinoma.. AB - Advances in imaging have led to a steady increase in the incidence of kidney cancer over the last two decades. There has ...
Metachronous renal cell carcinoma after radical nephrectomy is extremely rare. Renal cell carcinoma commonly metastasizes to distant organs. However, metastasis to the urinary bladder is very uncommon. Herein, we report a case of metachronous renal cell carcinoma with metastasis to the urinary bladder, left acetabulum, left rib, lungs, thyroid, right renal vein and inferior vena cava. The patient had undergone a left-sided radical nephrectomy 28 years ago. The pathological diagnosis of a fragment of the bladder tumor was consistent with Fuhrman grade 2 clear cell renal cell carcinoma. Although metachronous renal cell carcinoma after radical nephrectomy is rare, active surveillance should be still considered. Renal cell carcinoma has shown to unusually metastasize to the urinary bladder, a rarely reported organ of metastasis. Treatment options, such as immunotherapy, are available to patients with such metastasis and long-term survivorship can be achieved.
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2 David M Gill1†, David D Stenehjem2†, Kinjal Parikh3, Jo
TY - JOUR. T1 - Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study. AU - Stroup, Sean P.. AU - Raheem, Omer A.. AU - Palazzi, Kerrin L.. AU - Liss, Michael A.. AU - Mehrazin, Reza. AU - Kopp, Ryan P.. AU - Patel, Nishant. AU - Cohen, Seth A.. AU - Park, Samuel K.. AU - Patterson, Anthony L.. AU - Kane, Christopher J.. AU - Millard, Frederick. AU - Derweesh, Ithaar H.. PY - 2013/4. Y1 - 2013/4. N2 - Objective: To compare outcomes of metastatic renal cell carcinoma (mRCC) patients who underwent primary cytoreductive nephrectomy (CRN), followed by adjuvant sunitinib therapy, vs those who underwent primary sunitinib therapy before planned CRN. Methods: This was a multi-institutional retrospective analysis of 35 mRCC patients from June 2005 to August 2009 (median follow-up, 28.5 months): 17 underwent primary CRN, followed by adjuvant sunitinib (group 1); 18 underwent primary sunitinib ...
This paper presents the conclusions of a workshop entitled Impact of Molecular Genetics on the Classification of Renal Cell Tumours, which was held in Heidelberg in October 1996. The focus on renal cell tumours excludes any discussion of Wilms tumour and its variants, or of tumours metastatic to the kidneys. The proposed classification subdivides renal cell tumours into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most commonly documented genetic abnormalities. Benign tumours are subclassified into metanephric adenoma and adenofibroma, papillary renal cell adenoma, and renal oncocytoma. Malignant tumours are subclassified into common or conventional renal cell carcinoma; papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and renal cell carcinoma, unclassified. This classification is based on current genetic knowledge, correlates with recognizable histological ...
TY - JOUR. T1 - The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. AU - Carrasco, Alonso. AU - Thompson, R. Houston. AU - Leibovich, Bradley C.. AU - Lohse, Christine M.. AU - Cheville, John C.. AU - Boorjian, Stephen A.. PY - 2014. Y1 - 2014. N2 - Objective: To evaluate the impact of histology on cancer-specific and overall survival for patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN). Materials and Methods: We retrospectively reviewed the data of 505 patients with mRCC who underwent CN at Mayo Clinic, Rochester, MN, USA, between 1970 and 2008. All specimen were re-reviewed by a single genitourinary pathologist. Survival was estimated using the Kaplan-Meier method and compared according to histology with the log-rank test. Cox proportional hazard regression models were used to evaluate the association of histology with outcome. Results: Forty (8%) patients with non-clear cell ...
TY - JOUR. T1 - Cloning of renal cell carcinoma relation gene. T2 - Construction of a cDNA subtractive library of human renal cell carcinoma and its significance. AU - Zhang, Qiang. AU - Mao, Ze Bin. AU - Zhang, Zhi Wen. AU - Xin, Dian Qi. AU - Guo, Ying Lu. PY - 2000/12/1. Y1 - 2000/12/1. N2 - To construct a cDNA subtractive library of human renal cell carcinoma (RCC) with technique called suppression subtractive hybridization. The library only contains the differently expressing cDNAs between RCC and normal kidney. Poly (A)+ RNA were isolated from cell lines of RCC and normal kidney respectively. Moreover, single-strand cDNAs and double-strand cDNAs were synthesized in turn. After enzyme restriction, cDNAs between 400600 bp were obtained. RCC cDNAs then were divided into two groups and ligated to the specific adaptor 1 and adaptor 2 respectively . After RCC cDNAs hybridized with normal kidney cDNA twice and underwent two times of nested PCR, then with arms of T/A plasmid vectors to set up the ...
Clear cell renal cell carcinoma is a complex disease with only partial response to therapy and scarce reliable clinical parameters indicative of progression and survival. Fibroblast activation protein expression has been correlated with prognosis in several malignancies but never in renal cancer. We aim to analyze the immunohistochemical expression of fibroblast activation protein in 208 clear cell renal cell carcinomas and to evaluate its impact on the prognosis and survival. A positive cytoplasmic immunostaining of this protein in the stromal fibroblasts associated to cancer cells is associated with large tumor diameter (≥ 4 cm), high-grade (G3/4) tumors, and high-stage (≥ pT3) tumors. Fibroblast activation protein-positive cases had significantly shorter survivals after 5 (P = .00015), 10 (P = .0000042), and 15 (P = .000043) years of follow-up, with a hazard ratio of 0.31. Multivariate analysis showed that fibroblast activation protein (P = .00117) was stronger than grade and stage in ...
TY - JOUR. T1 - Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma. AU - Buck, M. J.. AU - Raaijmakers, L. M.. AU - Ramakrishnan, S.. AU - Wang, D.. AU - Valiyaparambil, S.. AU - Liu, S.. AU - Nowak, N. J.. AU - Pili, Roberto. PY - 2014/10/9. Y1 - 2014/10/9. N2 - Recent studies have demonstrated that in clear cell renal cell carcinoma (ccRCC) several chromatin remodeling enzymes are genetically inactivated. Although, growing evidence in cancer models has demonstrated the importance of epigenetic changes, currently only changes in DNA methylation can be accurately determined from clinical samples. To address this limitation, we have applied formaldehyde-assisted isolation of regulatory elements (FAIREs) combined with next-generation sequencing (FAIRE-seq) to identify specific changes in chromatin accessibility in clinical samples of ccRCC. We modified the FAIRE procedure to allow us to examine chromatin accessibility for small samples of solid tumors. ...
Human Kidney Slide (Clear Cell Renal Cell Carcinoma) (5 slides/pk) Slide for IHC HTS-10405 Human Kidney Slide (Clear Cell Renal Cell Carcinoma) (5 slides/pk) Slide for IHC HTS-10405
Background:It has been suggested that the apparent protective effect of alcohol intake on renal cell carcinoma may be due to the diluting effect of carcinogens by a high total fluid intake. We assessed the association between intakes of total fluids and of specific beverages on the risk of renal cell carcinoma in a large prospective cohort of UK women.Methods:Information on beverage consumption was obtained from a questionnaire sent 3 years after recruitment into the Million Women Study. Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for renal cell carcinoma associated with beverage consumption adjusted for age, region of residence, socioeconomic status, smoking, and body mass index.Results:After an average of 5.2 years of follow-up, 588 cases of renal cell carcinoma were identified among 779 369 women. While alcohol intake was associated with a reduced risk of renal cell carcinoma (RR for 2 vs 1 drink per day: 0.76; 95% CI: 0.61-0.96; P for
Clear cell renal cell carcinoma (ccRCC) is the most common pathological subtype of renal cell carcinoma, and immune-related genes (IRGs) are key contributors to its development. In this study, the gene expression profiles and clinical data of ccRCC patients were downloaded from The Cancer Genome Atlas database and the cBioPortal database, respectively. IRGs were obtained from the ImmPort database. We analyzed the expression of IRGs in ccRCC, and discovered 681 that were differentially expressed between ccRCC and normal kidney tissues. Univariate Cox regression analysis was used to identify prognostic differentially expressed IRGs (PDEIRGs). Using Lasso regression and multivariate Cox regression analyses, we detected seven optimal PDEIRGs (PLAU, ISG15, IRF9, ARG2, RNASE2, SEMA3G and UCN) and used them to construct a risk model to predict the prognosis of ccRCC patients. This model accurately stratified patients with different survival outcomes and
1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119-32 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69:7-34 3. Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A. et al. Renal Mass and Localized Renal Cancer: AUA Guideline. The Journal of urology. 2017;198:520-9 4. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M. et al. EAU guidelines on renal cell carcinoma: 2014 update. European urology. 2015;67:913-24 5. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894-906 6. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. European urology. 2011;59:543-52 7. Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC. et al. Lymph node dissection at the time of radical ...
TY - JOUR. T1 - Acquired cystic disease associated renal cell carcinoma. AU - Bakkannavar, Shankar M.. AU - Velayudhan, Dewaraj. AU - Prabhu, Ravindra. AU - Ramnarayan, K.. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Acquired cystic disease predisposes to renal cell carcinoma. We describe a patient who had received kidney transplant 7 years back with normal allograft function who suffered sudden cardiac death at home and was discovered to have acquired cystic disease and renal cell carcinoma in her native kidneys. This case highlights the need to assess native kidneys periodically after kidney transplant.. AB - Acquired cystic disease predisposes to renal cell carcinoma. We describe a patient who had received kidney transplant 7 years back with normal allograft function who suffered sudden cardiac death at home and was discovered to have acquired cystic disease and renal cell carcinoma in her native kidneys. This case highlights the need to assess native kidneys periodically after kidney ...
TY - JOUR. T1 - Morphologic and molecular characterization of renal cell carcinoma in children and young adults. AU - Bruder, Elisabeth. AU - Passera, Oliver. AU - Harms, Dieter. AU - Leuschner, Ivo. AU - Ladanyi, Marc. AU - Argani, Pedram. AU - Eble, John N.. AU - Struckmann, Kirsten. AU - Schraml, Peter. AU - Moch, Holger. PY - 2004/9/1. Y1 - 2004/9/1. N2 - A new WHO classification of renal cell carcinoma has been introduced in 2004. This classification includes the recently described renal cell carcinomas with the ASPL-TFE3 gene fusion and carcinomas with a PRCC-TFE3 gene fusion. Collectively, these tumors have been termed Xp11.2 or TFE3 translocation carcinomas, which primarily occur in children and young adults. To further study the characteristics of renal cell carcinoma in young patients and to determine their genetic background, 41 renal cell carcinomas of patients younger than 22 years were morphologically and genetically characterized. Loss of heterozygosity analysis of the von ...
Through combined deletion of Vhl, Trp53 and Rb1 in renal epithelial cells, the authors develop a new mouse model of renal cell carcinoma that recapitulates the cellular and molecular features of a large proportion of human tumors. This model uncovers a role for primary-cilium-related genes in the development of the disease and provides a reliable platform for preclinical therapeutic studies. Clear cell renal cell carcinomas (ccRCCs) frequently exhibit inactivation of the von Hippel-Lindau tumor-suppressor gene, VHL, and often harbor multiple copy-number alterations in genes that regulate cell cycle progression. We show here that modeling these genetic alterations by combined deletion of Vhl, Trp53 and Rb1 specifically in renal epithelial cells in mice caused ccRCC. These tumors arose from proximal tubule epithelial cells and shared molecular markers and mRNA expression profiles with human ccRCC. Exome sequencing revealed that mouse and human ccRCCs exhibit recurrent mutations in genes associated with
Bristol-Myers Squibb has announced the early closure of its phase 3 CheckMate-025 trial evaluating nivolumab (Opdivo) compared with everolimus for the treatment of previously-treated patients with advanced or metastatic renal cell carcinoma.. The study was stopped early because an independent Data Monitoring Committee assessment found that nivolumab is superior to everolimus in this patient population.. The results of CheckMate-025 mark the first time an Immuno-Oncology agent has demonstrated a survival advantage in advanced renal cell carcinoma, a patient group that currently has limited treatment options, said Michael Giordano, senior vice president, Head of Development, Oncology, Bristol-Myers Squibb. Through our Opdivo clinical development program, we aim to redefine treatment expectations for patients with advanced RCC by providing improved survival.. For the open-label trial, 821 previously-treated patients with advanced or metastatic clear-cell renal cell carcinoma were randomly ...
TY - JOUR. T1 - Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance. AU - Sorokin, Igor. AU - Canvasser, Noah E.. AU - Margulis, Vitaly. AU - Lotan, Yair. AU - Raj, Ganesh. AU - Sagalowsky, Arthur I. AU - Gahan, Jeffrey. AU - Cadeddu, Jeffrey A. PY - 2017. Y1 - 2017. N2 - Purpose: The overall recurrence rate of T1 renal cell carcinoma is low. We evaluated abdominal imaging after partial nephrectomy based on current guidelines for T1 renal cell carcinoma surveillance. Materials and Methods: We retrospectively reviewed the records of patients with T1 renal cell carcinoma who underwent partial nephrectomy between 2006 and 2012 followed by abdominal imaging at our institution. Primary and secondary outcomes were the incidence and timing, respectively, of imaging diagnosed abdominal recurrences. A literature review was performed to summarize prior reports of recurrence incidence and timing after partial nephrectomy for T1 disease. Results: A total of 160 ...
Background and objective: Clear Cell Renal Cell Carcinoma (CCRCC) is the most common adult renal neoplasm. Staging and grading of RCC are important predictors of survival. Fuhrman nuclear grading is widely used for CCRCC, the subjective nature of which has prompted more objective methods to evaluate nuclear features. Furthermore, Ki-67, a reliable marker of cellular proliferation may provide another variable for assessment of the biological behavior of RCC. The aim of this research was to study nuclear morphometry and Fuhrman nuclear grading of clear cell RCC, and to assess their relationship with the Ki-67 index. Methods: Hematoxylin and eosin slides of forty cases of CCRCC were retrieved and studied for pathologic variables, including Fuhrman nuclear grade, pathological tumor and node stage. Nuclear morphometric analysis was performed using computer-assisted image analysis. The relationship between Fuhrman nuclear grading, pathologic stage, tumor size, nuclear morphometry and proliferative index were
ABSTRACT. Cell cycle regulation in human renal cell carcinoma. Ylva Hedberg, Departments of Medical Biosciences, Pathology, and Surgical and. Perioperative Sciences, Urology Andrology, Umeå University, Sweden. Deregulated growth control is a hallmark of neoplasia potentially caused by aberrant expression of cell cycle regulatory proteins. The importance of such aberrations in human renal cell carcinoma (RCC) has not been fully clarified. Therefore, the protein expressions of several G1/S regulatory proteins in human RCC were evaluated and their relation to clinico-pathological data was examined.. Western blotting and immunohistochemistry were used to detect the proteinexpression of cyclin D1, D3, and E in 80 RCCs. Most tumors expressed higher levels of cyclin D1 (75%) and cyclin E (65%) compared to corresponding normal kidney cortex. In contrast, only 16 % of the tumors had high levels of cyclin D3. In conventional RCCs, low levels of cyclin D1 were associated with large tumor size, aneuploidy ...
TY - JOUR. T1 - A case of sarcomatoid renal cell carcinoma (RCC) with lower GI bleeding. AU - Salwa, Siti M.S.. AU - Firdaus, Mohd C.A.. AU - Goh, Eng Hong. AU - Tan, Guan Hee. AU - Singam, Praveen. AU - Fam, Xeng Inn. PY - 2017/7/1. Y1 - 2017/7/1. UR - http://www.scopus.com/inward/record.url?scp=85032032940&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85032032940&partnerID=8YFLogxK. M3 - Letter. AN - SCOPUS:85032032940. VL - 22. SP - 152. EP - 153. JO - Surgical Chronicles. JF - Surgical Chronicles. SN - 1108-5002. IS - 3. ER - ...
The results of a phase III trial comparing two commonly used drugs in the second-line treatment of renal cell carcinoma suggest that temsirolimus does not improve survival over sorafenib in the second line setting.. The two drugs inhibit different targets: temsirolimus targets mTOR, which regulates cell growth and proliferation, while sorafenib inhibits several tyrosine kinases, including VEGF receptors.. This is the first head-to-head phase III trial comparing a VEGF inhibitor to an mTOR inhibitor in renal cell carcinoma, reporting final results. Hence, this trial will have important treatment implications for patients and physicians, noted Dr Thomas Hutson from Texas Oncology-Baylor Charles A Sammons Cancer Center in Texas, USA.. Temsirolimus had demonstrated an overall survival benefit compared to interferon alfa in previously untreated patients with advanced renal cell carcinoma and poor prognostic features, but the drugs efficacy after treatment with a VEGF inhibitor was not known, Dr ...
Metastatic tumors in the paranasal sinuses are very rare. The origin of metastatic tumors in the paranasal sinuses is often renal cancer. Renal cell carcinomas are known for their tendency for early metastasis, and symptoms due to the metastatic lesion may be the only initial manifestation. In this paper, we deal with the case of a 35-year-old male patient who presented with a mass in the left maxillary region. The presence of a primary renal cell carcinoma was recognized only after surgical removal of the metastatic tumor. The presentation, diagnosis and treatment of this tumor are discussed with a review of the literature.
BACKGROUND: The use of cytoreductive nephrectomy (CN) selectively for patients who show a favorable response to upfront systemic therapy may be an approach to select optimal candidates with metastatic renal cell carcinoma (mRCC) who are most likely to benefit.. OBJECTIVE: We sought to characterize outcomes of deferred CN (dCN) after upfront sunitinib, outcomes relative to sunitinib alone, and outcomes of CN followed by sunitinib.. DESIGN, SETTING, AND PARTICIPANTS: We used the prospectively maintained International mRCC Database Consortium (IMDC) database to identify patients with newly diagnosed mRCC (2006-2018).. INTERVENTION: Sunitinib alone, upfront CN followed by sunitinib, sunitinib followed by dCN.. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes were overall survival (OS) and time to sunitinib treatment failure (TTF). Kaplan-Meier and multivariable Cox regression analyses were performed; dCN was analyzed as a time-varying covariate to account for immortal time bias.. RESULTS AND ...
TY - JOUR. T1 - Prognostic significance of high nuclear grade in patients with pathologic t1a renal cell carcinoma. AU - Suzuki, Kenjiro. AU - Mizuno, Ryuichi. AU - Mikami, Shuji. AU - Tanaka, Nobuyuki. AU - Kanao, Kent. AU - Kikuchi, Eiji. AU - Miyajima, Akira. AU - Nakagawa, Ken. AU - Oya, Mototsugu. PY - 2012/9/1. Y1 - 2012/9/1. N2 - Objective: A reliable prognostic indicator in patients with pathologic T1a renal cell carcinoma has not yet been fully elucidated. The aim of this study was to investigate the prognosis of pathologic T1a renal cell carcinoma cases with a special focus on pathological factors. Methods: The study population consisted of 338 patients diagnosed with solitary renal cell carcinoma at our hospital between 1996 and 2009. The relationship between disease progression and clinicopathologic features was analyzed retrospectively to determine if it affected recurrence and distant metastasis. Results: The Fuhrman nuclear grade distribution between the tumors was 1, 2, 3 and 4 ...
Preliminary data from an interim analysis of an ongoing phase III clinical trial of investigational temsirolimus (CCI-779) for the treatment of advanced renal cell carcinoma showed that single-agent therapy with temsirolimus significantly increased overall survival as a first-line treatment of patients with advanced disease and poor-risk features compared to interferon-alpha, a treatment for advanced renal cell carcinoma. In the trial, patients who were treated with temsirolimus alone experienced a 3.6-month, or 49%, increase in median overall survival time compared with patients treated with interferon-alpha alone (10.9 vs 7.3 months, P = .0069). 1
Objective: Our study aims to investigate the mechanism of the miR-129-5p/SPN axis in clear cell renal cell carcinoma (ccRCC), providing a novel direction for the targeted therapy of ccRCC. Methods: Bioinformatics methods were implemented to find the dif...
The bevacizumab experience in advanced renal cell carcinoma Lauren C Harshman, Sandy SrinivasDivision of Oncology, Stanford University School of Medicine, Stanford, California, USAAbstract: Bevacizumab in combination with interferon alfa is now approved for treatment-naïve advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response rates of 30% and progression-free survival rates of 9–10 months are ­comparable to the other approved first-line multityrosine kinase inhibitors, sunitinib and pazopanib. Its advantages include a different toxicity profile and assurance of ­administration compliance given its intravenous formulation. Enthusiasm for its use is blunted by the increased costs, the potential infusion-related reactions, the associated interferon-related toxicities, and the inconvenience of its nonoral formulation. Further study is warranted to assess its efficacy both as a single agent and in combination with the targeted agents and other
TY - JOUR. T1 - Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR). T2 - final results from a randomised, open-label, phase 3 trial. AU - Choueiri, Toni K.. AU - Escudier, Bernard. AU - Powles, Thomas. AU - Tannir, Nizar M.. AU - Mainwaring, Paul N.. AU - Rini, Brian I.. AU - Hammers, Hans J.. AU - Donskov, Frede. AU - Roth, Bruce J.. AU - Peltola, Katriina. AU - Lee, Jae Lyun. AU - Heng, Daniel Y C. AU - Schmidinger, Manuela. AU - Agarwal, Neeraj. AU - Sternberg, Cora N.. AU - McDermott, David F.. AU - Aftab, Dana T.. AU - Hessel, Colin. AU - Scheffold, Christian. AU - Schwab, Gisela. AU - Hutson, Thomas E.. AU - Pal, Sumanta. AU - Motzer, Robert J.. AU - METEOR investigators. PY - 2016/7/1. Y1 - 2016/7/1. N2 - Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma ...
BACKGROUND: The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines. METHODS: Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines. RESULTS: Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT ...
Everolimus (E) and axitinib (A) have been standard treatments for patients with metastatic renal cell carcinoma after failure of first-line therapy (1L) with vascular endothelial growth factor-targeted therapy.
Adding chemical shift techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment for these patients.. The study, conducted at Massachusetts General Hospital in Boston, included 156 patients with proven renal cell cancer. Clear cell renal carcinoma contains microscopic areas of fat, which is not seen on conventional imaging, said Dr. Azadeh Elmi, lead author of the study. Chemical shift MRI enables us to quantify even small amounts of fat, she said. The study found that chemical shift MRI was about 83% accurate in differentiating clear cell renal cell carcinoma from other types of kidney cancer.. Clear cell type is the most common type of kidney cancer, and it has the greatest potential to metastasize, said Dr. Elmi. Chemical shift MRI is a protocol that can be readily performed in kidney MRI at no additional cost, she said. As we are moving toward less ...
Patients with advanced renal cell carcinoma (RCC) are classified according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria in three risk-groups: favourable, intermediate and poor. To our knowledge there is only one study which examined the poor risk group (Hudes et al.), which led to the approval of temsirolimus in this population. However temsirolimus demonstrated a low response rate of 8.6% according to Response Evaluation Criteria In Solid Tumor (RECIST) criteria and a Progression free Survival (PFS) of 5.5 months and not all patients are suitable for temsirolimus treatment.. Thus, in clinical routine high-risk patients are also treated with multi Tyrosinkinase Inhibitors (mTKI). To date, a prospective data acquisition and control of effectiveness of a mTKI-treatment in high-risk patients has not been conducted.. Pazopanib was recently approved for the first-line treatment of advanced renal cell carcinoma in Europe and the USA. In the pivotal Phase III trial only nine patients in ...
TY - JOUR. T1 - Rising incidence of renal cell carcinoma in Ireland. AU - Falebita, Opeyemi A.. AU - Mancini, Silvia. AU - Kiely, Eamonn. AU - Comber, Harry. PY - 2009/3. Y1 - 2009/3. N2 - Objective: To determine the trend in the incidence of renal cell carcinoma in Ireland, and evaluate changes in the modes of presentation and outcomes. Methods: Data on all histologically diagnosed renal cancers in Ireland over a 12-year period (1994-2005) were retrieved from the database of the National Cancer Registry of Ireland. Data on all renal cancer deaths in Ireland in the period 1994-2004 were obtained from the Central Statistics Office. Results: There were 2,485 cases of renal cell carcinoma from 1994 to 2005, of which 64% were in males and 36% in females. The average age of females at diagnosis fell from 63 years in 1994 to 58 years in 2005, with little change in the average age in males. The age-adjusted incidence of renal cell carcinoma per 100,000 person-year increased from 5.2 in 1994 to 6.8 in ...
Thomas E. Hutson, Long H. Dang, Richard C. Lauer, Alexander Starodub, Ralph J. Hauke, Matt D. Galsky, Kathryn A. Bylow, Theodore Logan, Charles Lance Cowey, David C. Bibby, Gabriel Kremmidiotis, Elizabeth E. Doolin, Tina C. Lavranos, Guru Sonpavde, Noah M. Hahn, Christopher Sweeney, John Sarantopoulos. Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors. J Clin Oncol 30, 2012 (suppl; abstr 4603) http://www.asco.org/ASCOv2/Meetings/Abstracts&vmview=abst_detail_view&confID=114&abstractID=91911 ...
Cytoreductive nephrectomy has been an integral part of management in metastatic renal cell carcinoma for patients with good performance status, based on the benefit shown by prospective trials in the interferon era and retrospective trials in the targeted therapies era.
Protein-coding mutations in clear cell renal cell carcinoma (ccRCC) have been extensively characterized, frequently involving inactivation of the von Hippel-Lindau (VHL) tumor suppressor. Roles for noncoding cis-regulatory aberrations in ccRCC tumorigenesis, however, remain unclear. Analyzing 10 primary tumor/normal pairs and 9 cell lines across 79 chromatin profiles, we observed pervasive enhancer malfunction in ccRCC, with cognate enhancer-target genes associated with tissue-specific aspects of malignancy. Superenhancer profiling identified ZNF395 as a ccRCC-specific and VHL-regulated master regulator whose depletion causes near-complete tumor elimination in vitro and in vivo. VHL loss predominantly drives enhancer/superenhancer deregulation more so than promoters, with acquisition of active enhancer marks (H3K27ac, H3K4me1) near ccRCC hallmark genes. Mechanistically, VHL loss stabilizes HIF2α-HIF1β heterodimer binding at enhancers, subsequently recruiting histone acetyltransferase p300 ...
Epithelial-to-mesenchymal transition (EMT) is important in tumor invasiveness and metastasis. We aimed to determine prognostic value of six key EMT markers (CDH1, CDH2, SNAI1, SNAI2, VIM, TWIST1) in clear cell renal cell carcinoma (ccRCC). A total of 533 ccRCC patients with RNASeq data from The Cancer Genome Atlas (TCGA) cohort were included for analysis. Gene expression of these EMT markers was compared between tumor and normal tissues based on Oncomine database and TCGA cohort. Their correlations with progression-free survival (PFS) and overall survival (OS) were also examined in both TCGA cohort and FUSCC (Fudan University Shanghai Cancer Center) cohort. Cox proportional hazards regression model and Kaplan-Meier plot were used to assess the relative factors. Functional enrichment analyses were utilized to describe biologic function annotations and significantly involved hallmarks pathways of each gene. We found that Epithelial marker, CDH1 expression
Chromophobe renal cell carcinoma is a rare type of kidney cancer that develops in cells that are involved in the production of urine. Cancers form when a change (mutation) in DNA causes certain cells to grow out of control, sometimes forming a lump or a tumor. Some of these cancerous cells can break off and spread to other parts of the body where they will continue to grow (metastasis). Chromophobe renal cell carcinoma usually occurs in adults between the ages of 40 and 60, although it can appear in all age groups. This type of carcinoma is associated with Birt-Hogg-Dubé syndrome, an inherited disorder caused by a mutation in the FLCN gene. The FLCN gene is involved in regulating cell growth, and a mutation in this gene can cause cells to grow out of control. This situation places affected individuals at higher risk of developing chromophobe renal cell carcinoma as well as noncancerous growths in the kidneys, lungs, and hair follicles. Common symptoms include the presence of blood in the urine, ...
Chromophobe renal cell carcinoma is a rare type of kidney cancer that develops in cells that are involved in the production of urine. Cancers form when a change (mutation) in DNA causes certain cells to grow out of control, sometimes forming a lump or a tumor. Some of these cancerous cells can break off and spread to other parts of the body where they will continue to grow (metastasis). Chromophobe renal cell carcinoma usually occurs in adults between the ages of 40 and 60, although it can appear in all age groups. This type of carcinoma is associated with Birt-Hogg-Dubé syndrome, an inherited disorder caused by a mutation in the FLCN gene. The FLCN gene is involved in regulating cell growth, and a mutation in this gene can cause cells to grow out of control. This situation places affected individuals at higher risk of developing chromophobe renal cell carcinoma as well as noncancerous growths in the kidneys, lungs, and hair follicles. Common symptoms include the presence of blood in the urine, ...
TY - JOUR. T1 - Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. AU - Stadler, Walter M.. AU - Figlin, Robert A.. AU - McDermott, David F.. AU - Dutcher, Janice P.. AU - Knox, Jennifer J.. AU - Miller, Wilson H.. AU - Hainsworth, John D.. AU - Henderson, Charles A.. AU - George, Jeffrey R.. AU - Hajdenberg, Julio. AU - Kindwall-Keller, Tamila L.. AU - Ernstoff, Marc S.. AU - Drabkin, Harry A.. AU - Curti, Brendan D.. AU - Chu, Luis. AU - Ryan, Christopher W.. AU - Hotte, Sebastien J.. AU - Xia, Chenghua. AU - Cupit, Lisa. AU - Bukowski, Ronald M.. PY - 2010/3/1. Y1 - 2010/3/1. N2 - BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval. METHODS: In this nonrandomized, open-label expanded access program, 2504 patients from the United States and Canada were treated with oral sorafenib 400 mg twice daily. Safety ...
To report on the perioperative outcomes of laparoscopic partial nephrectomy (LPN) for multilocular cystic renal cell carcinoma (MCRCC) and evaluate the feasibility of this minimally invasive technique as a potential gold standard treatment for MCRCC. We retrospectively reviewed the database of surgically pathological findings of patients who were diagnosed with MCRCC at Peking University First Hospital and Chinese PLA General Hospital (Beijing, China) between May 2009 and January 2013. A total of 42 patients with an average age of 48.3 years who were treated with LPN were collected. The patients perioperative outcomes were reported and analyzed. All operations were performed successfully without massive hemorrhage or open conversion. None of patients received lymph node dissection or metastasectomy. Two patients required postoperative transfusion with a mean amount of 175 cc packed red blood cells. Only three patients experienced mild postoperative complications. The mean operative time was 2.4 ± 1.2
TY - JOUR. T1 - Prognostic Significance of Gremlin1 (GREM1) Promoter CpG Island Hypermethylation in Clear Cell Renal Cell Carcinoma. AU - van Vlodrop, Iris J. H.. AU - Baldewijns, Marcella M. L.. AU - Smits, Kim M.. AU - Schouten, Leo J.. AU - van Neste, Leander. AU - Van Criekinge, Wim. AU - van Poppel, Hein. AU - Lerut, Evelyne. AU - Schuebel, Kornel E.. AU - Ahuja, Nita. AU - Herman, James G.. AU - de Bruine, Adriaan P.. AU - van Engeland, Manon. PY - 2010/2. Y1 - 2010/2. U2 - 10.2353/ajpath.2010.090442. DO - 10.2353/ajpath.2010.090442. M3 - Article. VL - 176. SP - 575. EP - 584. JO - American Journal of Pathology. JF - American Journal of Pathology. SN - 0002-9440. IS - 2. ER - ...
We have recently shown that parathyroid hormone-related protein (PTHrP), a cytokine-like polyprotein, is critical for human renal cell carcinoma (RCC) growth by inhibiting tumor cell apoptosis. Here, we have explored mechanisms by which PTHrP controls tumor cell survival. Using specific inhibitors of phosphoinositide 3-kinase (PI3K) and depletion of Akt kinase by RNA interference, we established that PTHrP is one of the main factor involved in the constitutive activation of this pathway in human RCC, independently of von Hippel-Lindau (VHL) tumor suppressor gene expression. Interestingly, PTHrP induced phosphorylation of Akt at S473 but had no influence on phosphorylation at T308. Through transfection with integrin-linked kinase (ILK) constructs and RNA interference, we provide evidence that ILK is involved in human RCC cell survival. PTHrP activates ILK which then acts as a phosphoinositide-dependent kinase (PDK)-2 or a facilitator protein to phosphorylate Akt at S473. Among other kinases ...
TY - JOUR. T1 - Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. AU - Hahn, Andrew W.. AU - Froerer, Camryn. AU - VanAlstine, Sidney. AU - Rathi, Nityam. AU - Bailey, Erin B.. AU - Stenehjem, David D.. AU - Agarwal, Neeraj. PY - 2018/10. Y1 - 2018/10. N2 - Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) are a mainstay of treatment for metastatic renal-cell carcinoma. Stool microbiome composition is predictive of response to immunotherapy and cytotoxic chemotherapy. Antibiotics targeting Bacteroides species are associated with improved progression-free survival while receiving first-line VEGF-TKIs. Background: Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) are a mainstay of treatment for metastatic renal-cell carcinoma. Stool microbiome composition is predictive of response to immunotherapy and cytotoxic chemotherapy. We sought to ...
Vascular endothelial growth factor (VEGF) functions as a regulator of neovascularization in malignant cells. VEGF as a mitogen is thought to alter renal cell carcinoma formation and tumor progression. We investigated the expression of the VEGF gene in order to evaluate its clinical significance in renal cell carcinoma. Tissue samples from 198 patients with renal cell carcinoma were examined with an immunohistochemical stain for the expression of the VEGF gene. The expression rate was compared to 34 normal renal cortical samples obtained from renal surgery from noncancer patients. There were significant differences between normal renal cortex (0%) and cancer tissue (54.5%) in positive staining of VEGF protein (P|0.001). With the progression of tumor grade, the positive rate of VEGF gene expression significantly increased. The expression rate of the VEGF gene in the advanced group, such as with lymph node involvement or vein invasion, was greater than that in the locally confined group (P|0.001). The
Despite multiple studies, many clinicopathologic issues about chromophobe renal cell carcinoma (RCC) remain contentious; for example, its biological behavior-whether better or similar to papillary RCC, the incidence of sarcomatoid features, and whether pathologic features such as necrosis, nuclear g
Germline mutations in the von Hippel-Lindau (VHL) tumor suppressor gene predispose individuals to clear cell renal carcinomas, hemangioblastomas, and pheochromocytomas. The VHL gene product forms an ubiquitin E3 ligase complex, with regulation of hypoxia-inducible factor alpha (HIF-α) as its best known function. Lack of VHL expression has been shown previously to sensitize renal cells to apoptosis caused by certain cellular stresses. In this report, the role of HIF-α in apoptosis was investigated using two parent VHL-null renal carcinoma cell lines. 786-O and RCC10 renal carcinoma cell lines with manipulated levels of VHL, HIF-1α, or HIF-2α were subjected to cellular stresses and analyzed by western blotting for the abundance of apoptotic markers. Cell lines expressing mutant VHL proteins that were unable to regulate HIF-α had increased levels of apoptosis when irradiated with ultraviolet (UV) light. The influences of the two major isoforms of HIF-α, HIF-1α and HIF-2α, on apoptosis, were
ABSTRACT Objective: To evaluate the preoperative imaging manifestation and therapeutic effect of laparoscopic simple enucleation (SE) for localized chromophobe renal cell carcinoma (chRCC).. Materials and Methods: Clinical data of 36 patients who underwent laparoscopic SE of localized chRCC at our institute were retrospectively analyzed. All patients underwent preoperative renal protocol CT (unenhanced, arterial, venous, and delayed images). CT scan characteristics were evaluated. After intraoperative occlusion of the renal artery, the tumor was free bluntly along the pseudocapsule and enucleated totally. The patients were followed up regularly after the operation.. Results: Mean tumor diameter was 3.9±1.0 cm, 80% of tumors were homogeneous and all the tumors had complete pseudocapsule. The attenuation values were slightly lower than normal renal cortex and degree of enhancement of the tumors were significantly lower than normal renal cortex. Mean operation time was 104.3±18.2 min. Mean warm ...
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant tumor susceptibility syndrome, and the disease-related gene has been identified as fumarate hydratase (fumarase, FH). HLRCC-associated kidney cancer is an aggressive tumor characterized by early metastasis to regional lymph nodes and distant organs. Since early diagnosis and provision of definitive therapy is thought to be the best way to reduce the tumor burden, it is widely accepted that germline testing and active surveillance for an at-risk individual from a family with HLRCC is very important. However, it still remains controversial how we should treat HLRCC-associated kidney cancer. We successfully treated the patient with locally advanced HLRCC-associated kidney cancer, who has received active surveillance because of at-risk individual, by radical nephrectomy and extended retroperitoneal lymph node dissection, and examined surgically resected samples from a molecular point of view. We recommended that 13 at-risk
Michael, A, Politi, E, Havranek, E, Corbishley, C, Karapanagiotou, L, Anderson, C, Relph, K, Syrigos, KN and Pandha, H (2007) Prognostic significance of erythropoietin expression in human renal cell carcinoma ...
TY - JOUR. T1 - Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma. T2 - A populationbased assessment. AU - Crépel, M.. AU - Jeldres, C.. AU - Perrotte, P.. AU - Capitanio, U.. AU - Isbarn, H.. AU - Shariat, S. F.. AU - Liberman, D.. AU - Sun, M.. AU - Lughezzani, G.. AU - Arjane, P.. AU - Widmer, H.. AU - Graefen, M.. AU - Montorsi, F.. AU - Patard, J. J.. AU - Karakiewicz, P. I.. PY - 2010/6/1. Y1 - 2010/6/1. UR - http://www.scopus.com/inward/record.url?scp=77953639123&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=77953639123&partnerID=8YFLogxK. U2 - 10.1016.2009.04.098. DO - 10.1016.2009.04.098. M3 - Comment/debate. AN - SCOPUS:77953639123. VL - 24. SP - 886. EP - 887. JO - Journal of Endourology. JF - Journal of Endourology. SN - 0892-7790. IS - 6. ER - ...
Movie 3) First Pass Perfusion Image 4. Perspective: Renal cell carcinoma typically presents with painless hematuria and flank mass. Prognosis depends on tumor staging and presence of metastases. Cardiac metastasis of renal cell cancer is not uncommon. There are two common modes of cardiac metastasis: contigous extension through the renal vein and inferior vena cava into the right heart chambers and metastasis by diffuse systemic spread (1, 2). Although contigous extension from the inferior vena cava is common, direct distant metastasis are not uncommon (3, 4). Transthoracic echocardiography is the first diagnostic tool in the assessment of patients with suspected cardiac metastasis of renal cell carcinoma. CMR compliments the echocardiography and the CT with its wider field of view and the ability to characterize tissue (2). CMR should be used to localize the extent of primary tumor within the inferior vena cava and in the cardiac chambers. CMRs unique tissue characterization qualities can ...
Discussion: Renal oncocytoma is a benign renal neoplasm which comprises 3-7 percent of adult kidney tumors. One half to two-thirds of these lesions are found incidentally. However, they can present with hematuria, flank pain and be palpable on clinical examination. Occasionally large bilateral tumors can present as renal failure. Oncocytomas have been reported in patients with Birt-Hogg-Dube and Von-Hippel Lindau syndromes. The most common cytogenetic abnormalities include loss of chromosomes 1 and y and translocations of 11q13. In very rare cases, both kidneys show diffuse involvement with macroscopic and microscopic oncocytoma, chromophobe renal cell carcinomas, and hybrid tumors with oncocytic changes of the adjacent renal tubules epithelium. These cases have been termed renal oncocytosis. The major differential diagnosis to consider is chromophobe renal cell carcinoma. Compared to oncocytoma, chromophobe renal cell carcinoma shows nuclear hyperchromasia with nuclear membrane irregularities. ...
Background Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cell carcinoma. In patients with ccRCC several prognostic markers have been suggested, enclosing epidermal growth factor receptor (EGFR) expression and chromosome 7 polysomy (C7p). Cancer cells addicted to EGFR bear activated mutations in the EGFR gene, and these mutations are useful in predicting susceptibility of ccRCC to EGFR inhibitors. The aim of this study was to evaluate the prognostic value of EGFR overexpression and C7p.. Patients and methods Archival specimens, coupled with clinical and survival data of 34 patients (20 men, 14 women, median age 58, range 42-79 years) who had undergone radical nephrectomy for ccRCC were analyzed. Immunohistochemistry and fluorescence in situ hybridization (FISH) specimens were sections of formalin-fixed paraffin-embedded tissue. EGFR expression was detected as membranous and cytoplasmic staining of neoplastic cells > 1%, and a ratio between ...
The purpose of this study is to evaluate the activity of RO4929097 in renal cell carcinoma patients that have failed therapy with VEGF/VEGFR directed ag
TY - JOUR. T1 - Association of the gross appearance of intratumoral vascularity at MDCT with the carbonic anhydrase IX score in clear cell renal cell carcinoma. AU - Young, Jonathan R. AU - Coy, Heidi. AU - Kim, Hyun J.. AU - Douek, Michael. AU - Sisk, Anthony. AU - Pantuck, Allan J.. AU - Raman, Steven S.. PY - 2018/12/1. Y1 - 2018/12/1. N2 - OBJECTIVE. The purpose of this study was to determine whether qualitative MDCT features are associated with the carbonic anhydrase IX (CAIX) score of clear cell renal cell carcinoma (RCC). The CAIX score has been previously found to have prognostic significance for disease-free survival, overall survival, and lymph node involvement. MATERIALS AND METHODS. A cohort of 105 histologically proven clear cell RCCs in patients who underwent preoperative four-phase renal mass MDCT was derived from 2001 to 2013. Two genitourinary radiologists evaluated each lesion for the gross appearance of intratumoral vascularity, calcification, enhancement pattern, necrosis, ...
TY - JOUR. T1 - Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma. T2 - A systematic review and meta-analysis. AU - Iwata, Takehiro. AU - Kimura, Shoji. AU - Foerster, Beat. AU - Abufaraj, Mohammad. AU - Karakiewicz, Pierre I.. AU - Preisser, Felix. AU - Nasu, Yasutomo. AU - Shariat, Shahrokh F.. N1 - Funding Information: Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.. PY - 2019/4. Y1 - 2019/4. N2 - Aim: To investigate the association of perioperative blood transfusion (PBT) with oncologic outcomes in patients with renal cell carcinoma (RCC), we conducted a systematic review and meta-analysis of the literature to clarify the long-term oncologic effect of PBT in patients undergoing nephrectomy for RCC. Materials and methods: We searched the MEDLINE, Web of Science, Cochrane Library and Scopus on 15th April 2018 to identify studies that compared patients who ...
Background: Renal Cell Carcinoma (RCC) is the ninth most common cancer worldwide, with about 338,000 new cases diagnosed in 2012. Especially metastatic renal cell carcinoma has still despite surgical cytoreduction, VEGF-tyrosine kinase inhibitors, mTOR inhibitors and first promising results of immunotherapies a very poor prognosis what implies an urgent need for additional therapies. Cardiac glycosides have come into the focus as potential cancer treatment option. They can have anti-proliferative and apoptotic characteristics in several cancer cell lines but affect only in a much lesser extent normal cell lines. MicroRNAs are small non-coding RNAs of 17-25 nucleotides length that widely exist and they play an important regulating role in many normal and pathophysiological cellular processes, as cell proliferation, differentiation, induction of apoptosis, tumorigenesis and tumor progression.. Material and Methods: Four renal cell carcinoma cell lines were treated with three different cardiac ...
Khaled, H., N.A. Lahloubi, and N. Rashad, Review on renal cell carcinoma and pregnancy: A challenging situation. J Adv Res, 2016. 7(4): p. 575-80. Brenner, B. and I. Avivi, Cancer in pregnancy: the role of thromboprophylaxis. Thromb Res, 2012. 129 Suppl 1: p. S20-1. Katayama, H., et al., A case of renal cell carcinoma with inferior vena cava tumor thrombus diagnosed during pregnancy. Urol Int, 2014. 92(1): p. 122-4. Ghanney EC., et al., Renal cell carcinoma with inferior vena cava thrombus extending to the right atrium diagnosed during pregnancy. Ther Adv Urol. 2017 Apr 16;9(6):155-159. Thompson, R.H., et al., Renal cell carcinoma in young and old patients--is there a difference? J Urol, 2008. 180(4): p. 1262-6; discussion 1266. Loughlin, K.R., The management of urological malignancies during pregnancy. Br J Urol, 1995. 76(5): p. 639-44. Shim, M.H., et al., Clinical characteristics and outcome of cancer diagnosed during pregnancy. 2016. 59(1): p. 1-8. Lawindy, S.M., et al., Important surgical ...
NEAUA 2019 Abstracts: Institutional Review Of Open Versus Laparoscopic Partial Nephrectomy For Surgical Treatment Of Renal Cell Carcinoma
Kidney renal clear cell carcinoma (KIRC) is the most common renal cell carcinoma (RCC). However, patients with KIRC usually have poor prognosis due to limited biomarkers for early detection and prognosis prediction. In this study, we analysed key genes and pathways involved in KIRC from an array dataset including 26 tumour and 26 adjacent normal tissue samples. Weighted gene co-expression network analysis (WGCNA) was performed with the WGCNA package, and 20 modules were characterized as having the highest correlation with KIRC. The upregulated genes in the tumour samples are involved in the innate immune response, whereas the downregulated genes contribute to the cellular catabolism of glucose, amino acids and fatty acids. Furthermore, the key genes were evaluated through a protein-protein interaction (PPI) network combined with a co-expression network. The comparatively lower expression of AGXT, PTGER3 and SLC12A3 in tumours correlates with worse prognosis in KIRC patients, while higher ...
Carcinogenesis is a multistep process which involves interplay between the tumour cells and the matrix proteins. This occurs by adherence between the tumour cells and proteins in the extracellular matrix. VHL mutation affects through the hypoxia inducible factor (HIF) and causes changes in various tissue proteins like VEGF, PDGF, TGF, Fibronectin and others. As not much literature is available, we aim to quantify the changes of fibronectin protein in renal cell carcinoma (RCC) tissue. This Prospective unbalanced case control study was conducted over a period of 18 months from April 2016 to September 2017. The patients undergoing nephrectomy for the diagnosis of RCC were included in the study after obtaining written informed consent. Patients were excluded from study, if normal renal tissue could not be identified in the resected kidney and if the artery clamp time to retrieval of tissue was more than 30 min. Fibronectin protein is estimated in the tumour tissue by gel electrophoresis and western
The Wilms tumor gene 1 (WT1) was first reported as a tumor suppressor gene in Wilms tumor. However, later studies have shown the oncogenic properties of WT1 in a variety of tumors. It was recently proposed that WT1 was a chameleon gene, due to its dual functions in tumorigenesis. We aimed to investigate the clinical significance of WT1 as biomarker in acute myeloid leukemia (AML) and clear cell renal cell carcinoma (ccRCC) and to elucidate the function of WT1 as an oncogene in squamous cell carcinoma of head and neck (SCCHN).. In AML, it was suggested that WT1 expression was an applicable marker of minimal residual disease (MRD). In adult patients with AML, we found a good correlation between WT1 expression levels normalized to two control genes, β-actin and ABL. Outcome could be predicted by a reduction in WT1 expression in bone marrow (≥ 1-log) detected less than 1 month after diagnosis, when β-actin was used as control. Also, irrespective of the control gene used, outcome could be ...
Long noncoding RNAs (lncRNAs) are involved in the tumorigenesis and progression of human cancers, including renal cell carcinoma (RCC). Small nucleolar RNA host gene 4 (SNHG4) is reported to play an essential role in tumor growth and progression. However, the molecular mechanisms and function of SNHG4 in RCC remain undocumented. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to examine expression levels of SNHG4 in RCC tissue samples and cell lines. Cell counting kit-8, western blotting, activities of caspase-3, -8, and -9, wound-healing, and transwell invasion assays were performed to explore cell proliferation, apoptosis, migration, and invasion. The interaction among SNHG4, miR-204-5p, and RUNX2 was verified by bioinformatic analysis, a luciferase gene report, qRT-PCR, western blot analysis, and RNA immunoprecipitation assays. Xenograft mouse models were carried out to examine the role of SNHG4 in RCC in vivo. SNHG4 was highly expressed in RCC tissue samples and cell lines,
This study was done to analyze the clinical characteristics of renal cell carcinoma (RCC) in Korean patients with von Hippel-Lindau (VHL) disease. Between January 1996 and July 2008, 1,514 patients were diagnosed with RCC and 24 patients were diagnos
A Case Report of Choroidal Metastasis from Renal Cell Carcinoma during Sunitinib Treatment: A Tumor Pharmacologic Sanctuary Abstract.
The etiology of renal cell carcinoma (RCC) is only partially understood, but a metabolic component appears likely. We investigated biomarkers of one-carbon metabolism and RCC onset and survival. Methods The European Prospective Investigation into Cancer and Nutrition (EPIC) recruited 385747 participants with blood samples between 1992 and 2000, and this analysis included 556 RCC case-control pairs. A subsequent replication study included 144 case-control pairs nested within the Melbourne Collaborative Cohort Study (MCCS). Plasma concentrations of vitamin B2, vitamin B6, folate, vitamin B12, methionine and homocysteine were measured in prediagnostic samples and evaluated with respect to RCC risk using conditional and unconditional logistic regression models, and to all-cause mortality in RCC cases using Cox regression models. All statistical tests were two-sided. Results EPIC participants with higher plasma concentrations of vitamin B6 had lower risk of RCC, the odds ratio comparing the 4th and ...
In the present study, we noted that treatment of the RCC cell lines Caki-1, KTC-26 and A498 with amygdalin caused significant inhibition of cell growth and proliferation. Similar growth reduction after amygdalin application has been noted in non-small cell lung cancer (19) and bladder cancer cells (18) in vitro, as well as cervical cancer cells in vivo (20). Based on our data we conclude that the inhibition of growth induced by amygdalin is not due to apoptosis or necrosis. Other cancer cells such as cervical, bladder and prostate cancer cells react to amygdalin with apoptosis, leading to growth inhibition (18,20,21). Thus, the mode of action of amygdalin seems to depend on the type of cancer.. Although inhibition of growth in all three RCC cell lines was accompanied by changes in the percentage of cells in different cell cycle phases, the changes were not homogeneous. Treatment of Caki-1 and A498 cells with amygdalin caused an increase in G0/G1-phase cells by reducing the S- (Caki-1 and A498) ...
Liu F, Chen Y, Chen B, Liu C, Xing J. Cancer Manag Res. 2019;11:10891-10900. At the authors request, the Editor-in-Chief and Publisher of Cancer Management...
Chinese Journal of Biology is a peer-reviewed, Open Access journal that publishes original research articles as well as review articles in all areas of biology.
BackgroundRenal cell carcinoma (RCC) is the tenth most commonly diagnosed cancer in the United States. While it is usually lethal when metastatic, RCC is successfully treated with surgery when tumors are confined to the kidney and have low tumor volume. Because most early stage renal tumors do not result in symptoms, there is a strong need for biomarkers that can be used to detect the presence of the cancer as well as to monitor patients during and after therapy.MethodsWe examined genome-wide DNA methylation alterations in renal cell carcinomas of diverse histologies and benign adjacent kidney tissues from 96 patients.ResultsWe observed widespread methylation differences between tumors and benign adjacent tissues, particularly in immune-, G-protein coupled receptor-, and metabolism-related genes. Additionally, we identified a single panel of DNA methylation biomarkers that reliably distinguishes tumor from benign adjacent tissue in all of the most common kidney cancer histologic subtypes, and a ...
Introduction: Significant racial disparities in survival for renal cell carcinoma (RCC) exist between whites and blacks. Differences in access to care and comorbidities are possible contributors. To investigate if racial disparities persist when controlling for access to care, we analyzed data from a single payer healthcare system. Methods: As part of a case-control study within the Kaiser Permanente Northern California system, pathologic and clinical records were obtained for RCC cases (2,152 white, 293 black) diagnosed from 1998 to 2008. Patient demographics, comorbidities, tumor characteristics, and treatment status were compared between whites and blacks. Overall survival and disease specific survival (DSS) were calculated by the Kaplan-Meier method. A Cox proportion hazards model was used to estimate the independent associations of race, comorbidity, and clinico-pathologic variables with DSS. Results: Compared to whites, blacks were diagnosed at a younger age (median 62 vs. 66 years, p|0.001), were
TY - JOUR. T1 - Renal cell carcinoma with inferior vena cava involvement. T2 - Prognostic effect of tumor thrombus consistency on cancer specific survival. AU - Mager, Rene. AU - Daneshmand, Siamak. AU - Evans, Christopher P.. AU - Palou, Joan. AU - Martínez-Salamanca, Juan I.. AU - Master, Viraj A.. AU - McKiernan, James M.. AU - Libertino, John A.. AU - Haferkamp, Axel. AU - Haferkamp, Axel. AU - Capitanio, Umberto. AU - Carballido, Joaquín A.. AU - Chantada, Venancio. AU - Chromecki, Thomas. AU - Ciancio, Gaetano. AU - Daneshmand, Siamak. AU - Evans, Christopher P.. AU - Gontero, Paolo. AU - González, Javier. AU - Hohenfellner, Markus. AU - Huang, William C.. AU - Koppie, Theresa M.. AU - Libertino, John A.. AU - Espinós, Estefanía Linares. AU - Lorentz, Adam. AU - Martínez-Salamanca, Juan I.. AU - Master, Viraj A.. AU - McKiernan, James M.. AU - Montorsi, Francesco. AU - Novara, Giacomo. AU - OMalley, Padraic. AU - Pahernik, Sascha. AU - Palou, Joan. AU - Moreno, José Luis ...
Bilateral synchronous renal cell carcinoma (RCC) is uncommonly encountered. Debate exists among urologists in managing these cases in a single surgery versus staged surgeries. We aim to report our experience in managing encountered cases using single-stage surgeries. Retrospective collection of cases with pathologically confirmed RCC that had single-stage bilateral renal surgery over the past 2 years. Three cases were identified. Patients were managed using bilateral transverse lateral lumbotomy. All patients did not have intraoperative or postoperative complications. Kidney function stayed stable after surgery. Single-stage bilateral renal surgery is a safe procedure. Bilateral transverse lateral lumbotomy allows for a fast and safe surgery with minimal complications. There is a possible histological disconcordance in bilateral synchronous RCC.. ...
Objective: The aim of this population-based study was to evaluate the impact of quality indicators on the adherence to guidelines for renal cell carcinoma (RCC).. Material and methods: Since 2005, virtually all patients with newly diagnosed RCC in Sweden have been registered in the National Swedish Kidney Cancer Register (NSKCR). The register contains information on histopathology, nuclear grade, clinical stage, preoperative work-up, treatment, recurrence and survival. In addition, a number of quality indicators have been measured in the register aiming to increase the quality of care. The quality indicators are: the coverage of the register, histology reports, preoperative chest computed tomography (CT), partial nephrectomy, laparoscopic surgery, centralization to high-volume hospitals and waiting times.. Results: A total of 8556 patients with diagnosed RCC were registered from 2005 to 2013 (99% coverage). In 2013, 99% of the histopathology reports were standardized. The number of patients with ...
A patient with abdominal discomfort, weight loss, and general weakness was discovered by way of ultrasound and computed tomography to have a tumor in the lower pole of the left kidney. At a second computed tomography examination, the mass had shrunken and air-fluid levels and contrast medium from previous examinations were evident, confirming a renocolic fistula. The patient underwent en bloc left radical nephrectomy with resection of the descending colon. Renal cell carcinoma was confirmed histologically. The patient has been free of disease for 4 years. Such fistulas are usually related to renal calculi or tuberculosis but, of late, more have been the result of iatrogenic trauma sustained during percutaneous renal procedures and lithotripsy. Use of computed tomography and other imaging methods should enable early detection of most renocolic fistulas, which usually are a late manifestation of advanced renal disease. ...
This Phase I/II radioimmunotherapy study was carried out to determine the maximum tolerated dose (MTD) and therapeutic potential of 131I-G250. Thirty-
Esophageal squamous cell cancer. Over-expression. 47%. Immunohistochemistry. [24]. Renal cell carcinoma. Under-expression. 100% ... "Increased expression of SET domain containing proteins and decreased expression of Rad51 in different renal cell carcinomas". ... "Elevated expression of Rad51 is correlated with decreased survival in resectable esophageal squamous cell carcinoma". J Surg ... "Association of BRCA1 with Rad51 in mitotic and meiotic cells". Cell. 88 (2): 265-75. doi:10.1016/s0092-8674(00)81847-4. PMID ...
Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the ... Primary renal cell carcinomas as well as metastatic cancers can affect the kidney. Kidney failure is defined by functional ... "Renal Cell Carcinoma". Medscape Reference. WebMD. Archived from the original on 7 March 2014. Retrieved 7 March 2014. "Prostate ... Transitional cell carcinoma or bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder ...
Lipworth L, Tarone RE, McLaughlin JK (December 2006). "The epidemiology of renal cell carcinoma". The Journal of Urology. 176 ( ... If the mutation inhibits programmed cell death, the cell can survive to become a cancer, a cell that does not function like a ... If the mutation inhibits programmed cell death, the cell can survive to become a cancer cell. Similarly, acrolein, which is ... Small Cell Lung Carcinoma (SCLC) is the most closely associated with almost 100% of cases occurring in smokers.[56] This form ...
Malignancy, e.g. renal cell carcinoma. Placement of topical tetracycline in a petrolatum base into a surgical site. The ... Oct 2000). "Myospherulosis in renal cell carcinoma". Arch Pathol Lab Med. 124 (10): 1476-9. doi:10.1043/0003-9985(2000)124. 2.0 ...
Lipworth, Loren; Tarone, Robert E.; McLaughlin, Joseph K. (2006). "The Epidemiology of Renal Cell Carcinoma". The Journal of ... Lipworth, Loren; Tarone, Robert E.; McLaughlin, Joseph K. (2006). "The Epidemiology of Renal Cell Carcinoma". The Journal of ...
Targeted therapy for the treatment of advanced renal cell carcinoma Immunotherapy Combinations for Renal Cell Carcinoma Offer ... implications for patients with advanced renal cell carcinoma Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma ... Everolimus for renal cell carcinoma: predictive factors for response and future directions. Medical Oncology Supplement. 2008. ... In: Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press. 2007. Contemporary Therapeutic Strategies ...
Lim, H.Y.; Yip, Y.M. (2015). "Metabolic signatures of renal cell carcinoma". Biochem Biophys Res Commun. 460 (4): 938-43. doi: ... She also studied metabolism within cancer cells and found aerobic respiration within mitochondria in cancer cells, which ...
ISBN 978-0-19-157556-3. Wah TM (August 2017). "Image-guided ablation of renal cell carcinoma". Clinical Radiology. Elsevier BV ... kidney tumors such as renal cell carcinoma can be treated with image guided ablation (RFA, MWA, cryotherapy) with similar ... "Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies". BJU ... Renal arterial ischemia can contribute to hypertension, which can be severe and refractory to medical therapy. Coronary Artery ...
Erel, Arzu; Ozsoy, Esra; University, Gazi (2001). "Livedo reticularis associated with renal cell carcinoma". International ... Livedo reticularis associated with renal cell carcinoma (rare) Buerger's disease (as an initial symptom) As a rare ... excessive red cells or platelets) Infections (infective endocarditis, syphilis, tuberculosis, Lyme disease) Associated with ... "Generalized livedo reticularis as the first sign of metastatic breast carcinoma". Clinical and Experimental Dermatology. 34 (2 ...
In 2007, mTORC1 inhibitors began being approved for treatments against cancers such as renal cell carcinoma. In 2008 they were ... Voss MH, Molina AM, Motzer RJ (Aug 2011). "mTOR inhibitors in advanced renal cell carcinoma". Hematology/Oncology Clinics of ... Codogno P, Meijer AJ (Nov 2005). "Autophagy and signaling: their role in cell survival and cell death". Cell Death and ... In order for cells to grow and proliferate by manufacturing more proteins, the cells must ensure that they have the resources ...
In some cases the renal cell carcinoma may be a manifestation of an undiagnosed hereditary leiomyomatosis and renal cell cancer ... Altman D, Yin L, Johansson A, Lundholm C, Grönberg H (2010). "Risk of Renal Cell Carcinoma After Hysterectomy". Archives of ... Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC (1999). "Increased risk of renal cell carcinoma subsequent to ... Hysterectomy may cause an increased risk of the relatively rare renal cell carcinoma. The increased risk is particularly ...
... a gene associated with papillary renal cell carcinoma". Cytogenet. Cell Genet. 92 (3-4): 326-32. doi:10.1159/000056922. PMID ... 1995). "Hereditary papillary renal cell carcinoma: clinical studies in 10 families". J. Urol. 153 (3 Pt 2): 907-12. doi:10.1016 ... In a subset of papillary renal cell carcinomas, a t(X;1)(p11;q21) chromosome translocation has been repeatedly reported and is ... Meloni AM, Dobbs RM, Pontes JE, Sandberg AA (1993). "Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic ...
In contrast, UQCRFS1 and complex III has been absent in renal cell carcinoma, though the mechanism is unknown. In addition to ... "Renal cell carcinoma and normal kidney protein expression". Electrophoresis. 18 (3-4): 599-604. doi:10.1002/elps.1150180343. ... "Renal cell carcinoma and normal kidney protein expression". Electrophoresis. 18 (3-4): 599-604. doi:10.1002/elps.1150180343. ... Molecular Cell. 67 (1): 96-105.e4. doi:10.1016/j.molcel.2017.06.001. PMID 28673544. Ohashi Y, Kaneko SJ, Cupples TE, Young SR ( ...
It has received approval for use as a treatment for renal cell carcinoma from US FDA (27 January 2012), EMA (13 September 2012 ... Escudier B, Gore M (2011). "Axitinib for the management of metastatic renal cell carcinoma". Drugs in R&D. 11 (2): 113-26. doi: ... "FDA Approves Inlyta for Advanced Renal Cell Carcinoma". Drugs.com. January 27, 2012. Fauber J, Chu E (Oct 27, 2014). "The ... "ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma". 7 Dec 2011. ALK1/VEGF Combo Active in Advanced RCC. Jan 2017 ...
... renal cell carcinoma, and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, ... November 2015). "Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma". The New England Journal of Medicine. 373 (19 ... as a second line treatment for renal cell carcinoma. Cabozantinib has not been tested in pregnant women; it causes harm to ... for treatment of people with advanced renal cell carcinoma (RCC). The approval was based on data from CABOSUN (NCT01835158), a ...
"Germline SDHB mutations and familial renal cell carcinoma". Journal of the National Cancer Institute. 100 (17): 1260-2. doi: ... Cell. 121 (7): 1043-57. doi:10.1016/j.cell.2005.05.025. PMID 15989954. S2CID 16697879. Horsefield R, Yankovskaya V, Sexton G, ... Rapid and uncontrolled cell division, along with the formation of new blood vessels, can lead to the development of tumors in ... Excess HIF stimulates cells to divide and triggers the production of blood vessels when they are not needed. ...
... renal cell carcinoma. Paul Van Riper, 97, American political scientist. Jamil Ahmad, 83, Pakistani author, heart attack. Nestor ... renal failure. Thomas Brennan, 74, Irish Olympic equestrian. C. C. Bridgewater, 70, American judge. Ian Brune, 64, South ...
... is indicated as a treatment for advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC) and ... advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive ... treatment with sorafenib prolongs progression-free survival in patients with advanced clear cell renal cell carcinoma in whom ... "Sorafenib in advanced clear-cell renal-cell carcinoma". New England Journal of Medicine. 356 (2): 125-34. doi:10.1056/ ...
... renal cell carcinoma of chromophobe, hybrid oncocytic, or oncocytoma histology; sebaceous carcinoma; and sex cord tumors with ... hereditary leiomyomatosis renal cell cancer (LRCC), hereditary papillary renal cell cancer (HPRCC), hereditary paraganglioma- ... The most common tumors in VHL are central nervous system and retinal hemangioblastomas, clear cell renal carcinomas, ... Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is an autosomal dominant cancer syndrome in which ...
Renal oncocytoma, a kidney tumour composed of oncocytes. Hurthle cell carcinoma, a variant of follicular thyroid carcinoma. ... Also known as: Hürthle cell (thyroid gland only) Oxyphilic cell, Askanazy cell Apocrine metaplasia (breast gland only). Derived ... An oncocyte is an epithelial cell characterized by an excessive number of mitochondria, resulting in an abundant acidophilic, ...
Medina Villaamil (2011-02-01). "Fructose transporter Glut5 expression in clear renal cell carcinoma". Oncology Reports. 25 (2 ... probably because β cells have low levels of GLUT5, a transporter protein at cell membranes for fructose. For a 50 gram ... The cells (enterocytes) that line children's small intestines have less affinity for fructose absorption than for glucose and ... However, insulin is capable of increasing the abundance and functional activity of GLUT5 in skeletal muscle cells. The initial ...
... tumour Wilms tumor Renal cell carcinoma Lupus nephritis Minimal change disease In nephrotic syndrome, the glomerulus has ... border cell Loop of Henle thin segment cell Thick ascending limb cell Kidney distal tubule cell Collecting duct principal cell ... A recessed area on the concave border is the renal hilum, where the renal artery enters the kidney and the renal vein and ... The renal sinus collectively contains the renal pelvis and calyces and separates these structures from the renal medullary ...
The symptoms and signs resolve if the renal cell carcinoma (or another associated tumor) is successfully ablated. It is due to ... Reversible hepatic dysfunction in renal cell carcinoma (author's transl)]". Wien Klin Wochenschr. 90 (8): 268-70. PMID 636440. ... syndrome is a constellation of signs and symptoms of liver dysfunction that arises due to presence of renal cell carcinoma, and ... release of IL-6 from cancerous cell. Maurice H. Stauffer, M.D., a gastroenterologist at the Mayo Clinic in Rochester, MN, first ...
The suggested role for this protein is in tumorigenesis of renal cell carcinoma. Two alternatively spliced transcript variants ... 2005). "Pathological characterization of Kank in renal cell carcinoma". Exp. Mol. Pathol. 78 (1): 41-8. doi:10.1016/j.yexmp. ... located at 9p24 is a growth suppressor of renal cell carcinoma". J Biol Chem. 277 (39): 36585-91. doi:10.1074/jbc.M204244200. ... V. The coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by analysis of cDNA clones from human cell line KG-1". DNA ...
1997). "Renal cell carcinoma and normal kidney protein expression". Electrophoresis. 18 (3-4): 599-604. doi:10.1002/elps. ... Cytogenet Cell Genet. 82 (1-2): 115-9. doi:10.1159/000015082. PMID 9763677. S2CID 46818955. Zong NC, Li H, Li H, Lam MP, ... Cytogenet Cell Genet. 82 (1-2): 114. doi:10.1159/000015081. PMID 9763676. S2CID 46861680. Ton C, Hwang DM, Dempsey AA, Liew CC ...
The medication is used to treat clear cell renal cell carcinoma, the most common histological subtype. The treatment phase is ... It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide. It is ... Pick, AM; Nystrom, KK (March 2012). "Pazopanib for the treatment of metastatic renal cell carcinoma". Clinical Therapeutics. 34 ... for use as a treatment for advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas. In Australia and New ...
"Expression of cadherin-8 in renal cell carcinoma and fetal kidney". International Journal of Cancer. 101 (4): 327-34. doi: ... cell-cell junction assembly. • calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules. • cell-cell ... cell-cell adherens junction. • cell surface. • catenin complex. Biological process. • response to cold. • cell adhesion. • ... integral membrane proteins that mediate calcium-dependent cell-cell adhesion. Mature cadherin proteins are composed of a large ...
It is over-expressed in VHL mutated clear-cell renal cell carcinoma (ccRCC) and hypoxic solid tumors, but is low-expressed in ... "Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau ... Girentuximab, an antibody to carbonic anhydrase IX, is an investigational agent in clinical trials for renal cell carcinoma.[10 ... Bedke J, Stenzl A (2013). "Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?". Expert ...
"Antigens recognized by autologous antibody in patients with renal-cell carcinoma". International Journal of Cancer. 83 (4): 456 ... epidermal cell fate specification. • positive regulation of cell proliferation. • Clara cell differentiation. • interleukin-4 ... auditory receptor cell fate commitment. • B cell differentiation. • regulation of gene expression. • Notch signaling pathway. • ... somatic stem cell population maintenance. • endocardium development. • cell fate commitment. • DNA recombination. • ...
Less frequently, renal cell carcinoma can be caused by this mutation. Paragangliomas related to SDHB mutations have a high rate ... "Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells". Mol. Cell ... Normal α-ketoglutarate does not permeate cell walls efficiently, and it is necessary to create a cell permeating derivative (e. ... Paraganglionic tissue is derived from the neural crest cells present in an embryo. Abdominal extra-adrenal paraganglionic cells ...
... almost all subtypes of renal cell carcinoma, nephrogenic adenomas, ovarian cancer cells, bladder, prostate, and endometrial ... Some studies have suggested that the renal PAX genes act as pro-survival factors and allow tumor cells to resist apoptosis. ... They play a role in the specification of the first renal cells of the embryo and remain essential players throughout ... Expression of PAX8 is increased in neoplastic renal tissues, Wilms tumors, ovarian cancer and Müllerian carcinomas. For this ...
... uterine and renal cell carcinoma among others ; as well as certain sarcomas and pseudomyxoma peritonei. ... cancer that begins in egg cells).. *Mucinous appendiceal carcinoma: A type of cancer that begins in cells that line the ... Most ovarian cancers are either ovarian epithelial carcinomas (cancer that begins in the cells on the surface of the ovary) or ... Thymoma and Thymic carcinoma: These tumors which arise from the thymus gland in the upper part of the chest overlying the heart ...
Small-cell carcinoma. *Soft-tissue sarcoma. *Spinal tumor. *Squamous cell carcinoma. *Stomach cancer ...
Glioblastomas are the most common primary malignancies to hemorrhage while thyroid, renal cell carcinoma, melanoma, and lung ... Hemorrhagic transformation of an ischemic infarct Cerebral venous thrombosis Sympathomimetic drug abuse Moyamoya Sickle cell ...
The glycogen phosphorylase monomer is a large protein, composed of 842 amino acids with a mass of 97.434 kDa in muscle cells. ... Grünfeld JP, Ganeval D, Chanard J, Fardeau M, Dreyfus JC (Jun 1972). "Acute renal failure in McArdle's disease. Report of two ... Shimada S, Matsuzaki H, Marutsuka T, Shiomori K, Ogawa M (July 2001). "Gastric and intestinal phenotypes of gastric carcinoma ... In fact, 70% of dimeric phosphorylase in the cell exists as bound to glycogen granules rather than free floating.[9] ...
EAU guidelines on renal cell carcinoma: the 2010 update. In: European Urology. Band 58, 2010, S. 398-406, doi:10.1016/j.eururo. ... Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III ... nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. In: Cancer Cell. Band 1, Nr. 2, März 2002, S. ... Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. In: The New England Journal of Medicine. Band ...
PTCH1 (Nevoid basal-cell carcinoma syndrome). *BMPR1A (BMPR1A juvenile polyposis syndrome). *IL2RG (X-linked severe combined ... Ultrasound of kidneys to rule out unilateral renal agenesis.. *Bone density scan (DXA) to check for osteoporosis or osteopenia. ... LHCGR (Luteinizing hormone insensitivity, Leydig cell hypoplasia, Male-limited precocious puberty). *FSHR (Follicle-stimulating ... Absence of one of the kidneys (unilateral renal agenesis)[2]. *Skeletal defects including split hand/foot (ectrodactyly), ...
Treatment of renal cell carcinoma with infliximab resulted in prolonged disease stabilization in certain patients. Etanercept ... positive regulation of heterotypic cell-cell adhesion. • negative regulation of mitotic cell cycle. • endothelial cell ... but it is produced also by a broad variety of cell types including lymphoid cells, mast cells, endothelial cells, cardiac ... NK cells, neutrophils, mast cells, eosinophils, and neurons.[5] TNFα is a member of the TNF superfamily, consisting of various ...
Renal cell cancer and melanoma are generally considered to be radioresistant but radiation therapy is still a palliative option ... 2005). "Cervix carcinoma". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium ... Targeting double-stranded breaks increases the probability that cells will undergo cell death. Cancer cells are generally less ... Fractionation allows normal cells time to recover, while tumor cells are generally less efficient in repair between fractions. ...
... and renal cell carcinoma.[4]. References[change , change source]. *↑ [http://firstaid.webmd.com/body-temperature WebMD Body ...
... and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to ... natural killer cell differentiation. • positive regulation of natural killer cell proliferation. • cell-cell signaling. • ... and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells ... cell maturation. • extrathymic T cell selection. • positive regulation of T cell proliferation. • regulation of defense ...
show that two genes encoding for has-miR-9 are significantly hypermethylated in clear cell renal carcinoma tumours. Ambros V ( ... status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma". ... Uchida N (2010). "MicroRNA-9 controls a migratory mechanism in human neural progenitor cells". Cell Stem Cell. 6 (4): 294-6. ... "MicroRNA-9 coordinates proliferation and migration of human embryonic stem cell-derived neural progenitors". Cell Stem Cell. 6 ...
The term 'crypt cell carcinoma' has been used for them, and though perhaps more accurate than considering them carcinoids, has ... Histologically, it forms clusters of goblet cells containing mucin with a minor admixture of Paneth cells and endocrine cells. ... Goblet cell carcinoid[edit]. Main article: Goblet cell carcinoid. This is considered to be a hybrid between an exocrine and ... Hepatocellular adenoma/Hepatocellular carcinoma. Urogenital. *Renal cell carcinoma. *Endometrioid tumor. *Renal oncocytoma ...
... is the second most common urological malignancy to be associated with paraneoplastic syndromes after renal cell carcinoma. ... The purpose of this clinical case demonstrates the aggressive nature of the neuroendocrine small cell carcinoma with rapid ... "Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies", Lancet, 341 (8836): 21-22, doi: ... a case report of Neuroendocrine Small Cell Carcinoma of the Endometrium presenting as Paraneoplastic Cushing's Syndrome". Facts ...
... and renal cell carcinoma, all of which may produce renin.[12] Hypertension secondary to other renal disorders[edit]. *Chronic ... The differential diagnosis of a renal tumor in a young patient with hypertension includes Juxtaglomerular cell tumor, Wilms' ... Kidney disease / renal artery stenosis - the normal physiological response to low blood pressure in the renal arteries is to ... it is thought that decreased perfusion of renal tissue due to stenosis of a main or branch renal artery activates the renin- ...
The most common medications affect mainly the fast-dividing cells of the body, such as blood cells and the cells lining the ... de Jonge MJ, Verweij J (Feb 2006). "Renal toxicities of chemotherapy". Seminars in Oncology. 33 (1): 68-73. PMID 16473645. doi: ... M - mitosis; where the cell divides to produce two daughter cells that continue the cell cycle. ... cells that produce white and red blood cells) are destroyed, meaning allogenic or autologous bone marrow cell transplants are ...
Feb 2007). "Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions ... inhibit cell proliferation of endothelial cells. thrombospondin. inhibit cell migration, cell proliferation, cell adhesion and ... inhibit cell proliferation and induce apoptosis of endothelial cells. endostatin. inhibit cell migration, cell proliferation ... inhibit cell proliferation and induce apoptosis of endothelial cells. endostatin. inhibit cell migration, cell proliferation ...
Micrograph of urethral cancer (urothelial cell carcinoma), a rare problem of the urethra. ... Renal tubule. *Proximal convoluted tubule. *Loop of Henle *Descending. *Thin ascending. *Thick ascending ... It also serves as a passage for urine to flow.[1] Urine typically contains epithelial cells shed from the urinary tract. Urine ... The epithelium of the urethra starts off as transitional cells as it exits the bladder. Further along the urethra there are ...
Some carcinomas are named for their or the putative cell of origin, (e.g.hepatocellular carcinoma, renal cell carcinoma). ... and sarcomatoid carcinoma (mixtures of spindle and giant cell carcinoma). Pleomorphic carcinoma contains spindle cell and/or ... spindle cell carcinoma (containing elongated cells resembling connective tissue cancers), giant cell carcinoma (containing huge ... Micrograph of a lung primary small cell carcinoma, a type of carcinoma. The clustered cancerous cells consist primarily of ...
... methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells". Cancer Research. 53 (5): 1064- ... Renal and fecal. Identifiers. IUPAC name. *(5R,5aR,8aR,9S)-5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-({4,6-O-[(R ... The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which ... It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body.[3] ...
"Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA ... Kidney injury, acute renal failure I Completed Quark Pharmaceuticals NCT00554359 Delayed graft function, complications of ... Cullen LM, Arndt GM (June 2005). "Genome-wide screening for gene function using RNAi in mammalian cells". Immunology and Cell ... RNAi is a valuable research tool, both in cell culture and in living organisms, because synthetic dsRNA introduced into cells ...
... subunit gene from a putative tumor suppressor gene region at chromosome 3p21.1 in conventional renal cell carcinoma". Gene. 264 ... "Cell. 143 (4): 628-38. PMC 3040441. . PMID 21074052. doi:10.1016/j.cell.2010.09.047. الوسيط ,السنة=. تم تجاهله (مساعدة); الوسيط ... predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas". British Journal of Cancer. 107 (2): ...
"Validation of housekeeping gene and impact on normalized gene expression in clear cell renal cell carcinoma: critical ... "Gene expression profile analysis of dbpA knockdown in colorectal cancer cells. ". Cell Biol Int. 2016. PMID 27569444. ... "DNA binding protein A expression and methylation status in hepatocellular carcinoma and the adjacent tissue. ". Int J Oncol. ... "Upregulation of human DNA binding protein A (dbpA) in gastric cancer cells. ". Acta Pharmacol Sin. 2009. PMID 19749785. ...
... end-stage renal failure and heart disease are caused by different mechanisms that are not related to stem cells. Also, some ... 1990). "Telomere reduction in human colorectal carcinoma and with ageing". Nature. 346: 866-868. doi:10.1038/346866a0. PMID ... First, different cells may have different lifespans even though they are originated from the same stem cells (See T-cells and ... doi:10.1016/j.cell.2005.01.027. Jones DL, et al. (May 2011). "Emerging Models and Paradigms for stem cell ageing". Nat Cell ...
Chemical inhibition of LDH A has demonstrated marked changes in metabolic processes and overall survival carcinoma cells. ... These ROS drive cancer cell proliferation by activating kinases that drive cell cycle progression growth factors at low ... Lactate dehydrogenase (LDH or LD) is an enzyme found in nearly all living cells (animals, plants, and prokaryotes). LDH ... In medicine, LDH is often used as a marker of tissue breakdown as LDH is abundant in red blood cells and can function as a ...
Renal disease. Patients who have uremia often have poor or absent appetite, vomiting and nausea. This can cause weight loss. ... from the cells to the most complex body functions, including:[51] ... hepatocellular carcinoma, pancreatic cancer), ovarian, hematologic or lung malignancies. ...
... transitional cell carcinoma of the bladder or other malignancies.[29] Myeloproliferative neoplasms, including acute leukemia, ... and drug dosing should be appropriately adjusted in the setting of renal dysfunction.[37] Drugs altering hepatic microsomal ... Elimination of T regulatory cells (CD4+CD25+ T cells) in naive and tumor-bearing hosts ... subsequently actively transported into cancer cells. Once in the cells, the prodrug was enzymatically converted into the active ...
"Expression of heat shock protein 70 in renal cell carcinoma and its relation to tumor progression and prognosis". Histology and ... Hsp70 is overexpressed in malignant melanoma[17] and underexpressed in renal cell cancer.[18][19] ... "Cell. 151 (6): 1308-18. doi:10.1016/j.cell.2012.10.051. PMC 3778871. PMID 23217712.. ... The Hsp70s are an important part of the cell's machinery for protein folding, and help to protect cells from stress.[2][3] ...
Targeting HIF2α in Clear-Cell Renal Cell Carcinoma. [Cancer Cell. 2016] ... Clear cell renal cell carcinoma (ccRCC) is characterized by inactivation of the von Hippel-Lindau tumour suppressor gene (VHL ... Targeting renal cell carcinoma with a HIF-2 antagonist.. Chen W1,2,3, Hill H1,2, Christie A1, Kim MS1,4, Holloman E1,2, Pavia- ... Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. [Eur Urol. 2017] ...
... treatment and resreatch studies about kidney and renal cell carcinoma for the medical professionals while caring for their ... The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate ... Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo ... associated with decreased odds of death versus radical nephrectomy among patients with cT1b but not cT2 renal cell carcinoma. ...
Gain a better understanding of cystic renal cell carcinoma and the best approaches to diagnosing and managing this uncommon ... Table 2. The character of cystic renal cell carcinoma concurrent renal cell carcinomas Pt. No.. Age (yr). Sex. Mass location ( ... Cystic renal cell carcinoma (CRCC) is relatively rare; it represents a special subtype of renal cell carcinoma (RCC) associated ... Cystic Renal Cell Carcinoma. A Report of 67 Cases Including 4 Cases With Concurrent Renal Cell Carcinoma. ...
Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes (tubules) in the kidney. ... Renal cell carcinoma is the most common type of kidney cancer in adults. It occurs most often in men 60 to 70 years old. ... Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes (tubules) in the kidney. ... Renal cell cancer treatment (PDQ) -- health professional version. www.cancer.gov/types/kidney/hp/kidney-treatment-pdq. Updated ...
Renal cell carcinoma is responsible for about 90 percent of kidney cancers in adults. Renal cell carcinoma appears to be caused ... a disease arising from malignant epithelial cells in the kidneys. ... Renal cell carcinoma, a disease arising from malignant epithelial cells in the kidneys. Renal cell carcinoma is responsible for ... science/renal-cell-carcinoma", "shareUrl": "https://www.britannica.com/science/renal-cell-carcinoma", "title": "Renal cell ...
Renal cell carcinoma is rarely detected in the early stages of disease, since there are often no obvious symptoms until the ... Renal Cell Carcinoma Diagnosis. News-Medical, viewed 20 October 2020, https://www.news-medical.net/health/Renal-Cell-Carcinoma- ... Renal Cell Carcinoma Diagnosis. News-Medical. 20 October 2020. ,https://www.news-medical.net/health/Renal-Cell-Carcinoma- ... Renal Cell Carcinoma Diagnosis. News-Medical. https://www.news-medical.net/health/Renal-Cell-Carcinoma-Diagnosis.aspx. ( ...
Learn more about renal cell carcinoma, or kidney cancer, and treatment options, including targeted therapy, courtesy of ... About renal cell carcinoma. Renal cell carcinoma, or RCC, develops in the lining of the kidneys tubes and grows into a mass or ... Treating renal cell carcinoma. Treatment plans for patients with advanced renal cell carcinoma (RCC) vary, but can often ... Become an ally in the fight against renal cell carcinoma. Visit www.AlliesinRCC.com to learn more about RCC. ...
Renal cell carcinoma occurs when cancer cells form in the tubules of the kidneys. Find out about the risks, symptoms, ... More in Fight for the Future with Renal Cell Carcinoma. *. 7 Tips to Stay on Track with Your At-Home Renal Cell Carcinoma Care ... Renal cell carcinoma, or RCC, is also called hypernephroma, adenocarcinoma of renal cells, or renal or kidney cancer. Learn the ... Renal cell carcinoma is the most common form of kidney cancer. But not all renal cell cancers are the same. Learn about the ...
Renal cell carcinoma (RCC) is a type of kidney cancer. Often, RCC has no initial symptoms. When symptoms and signs appear they ... Renal cell cancer (also termed renal cell carcinoma or RCC) is a disease that occurs when certain kidney cells become malignant ... The most common type is clear cell (70%), with cells that appear pale or clear. Papillary renal cell cancers (10%) form little ... Treatment of renal cell carcinoma. The treatment of kidney cancer is often decided by the patient and physician and is based on ...
SRCCs were originally considered to be carcinosarcomas or to be renal sarcomas in cases in which the sarcomatous component had ... T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas. J Urol. 2005 Oct. 174(4 ... Rhabdoid renal cell carcinoma arising from a clear cell renal cell carcinoma. The clear cell component is golden in color with ... Sarcomatoid renal cell carcinoma arising from a clear cell renal cell carcinoma (lower left). Clear cell areas are golden in ...
Diagnosed with renal cell carcinoma at just 30, Lisa Velasquez is celebrating her 10th year of remission. Learn more about ... She was diagnosed with renal cell carcinoma (RCC) when she was just 30. ... I kept thinking about a dear friends father who had been diagnosed with renal cancer and died six months later. ...
Renal cell carcinoma (see the image below) is the most common type of kidney cancer in adults. It accounts for approximately 3 ... Go to Clear Cell Renal Cell Carcinoma and Sarcomatoid and Rhabdoid Renal Cell Carcinoma for complete information on these ... encoded search term (Renal Cell Carcinoma) and Renal Cell Carcinoma What to Read Next on Medscape ... H and E, high power of a clear cell renal cell carcinoma. The tumor cells have abundant pale "clear" cytoplasm. ...
Latest Renal Cell Carcinoma Meetings * No recent meetings in Renal Cell Carcinoma ... Clinical Focus In Renal Cell Carcinoma: Clues from Gene Studies Mutations in four genes appear to play a key role in the origin ... Clinical Focus in Renal Cell Carcinoma: Indolent Disease Tx Initial observation and intermittent therapy might be options for ... VIENNA -- Metastatic renal cell carcinoma responded about as well to the oral targeted agent pazopanib (Votrient) as to oral ...
Renal cell carcinoma is the 14th most common cancer worldwide, with the highest incidence rates in North America, Europe, and ... finds that ablative techniques have widened the range of treatment options available to patients with renal cell carcinoma.. ... the advent of ablative techniques has widened the range of treatment options available to patients with renal cell carcinoma ( ... better preserves renal parenchymal volume (which correlates with overall renal function), reduces recovery time, and can result ...
... Mohammad Kazem Moslemi,1 Shabir Al-Mousawi,2 and Mohammad Hasan Dehghani ... Mohammad Kazem Moslemi, and Mehdi Abedinzadeh, "Chronic headache as the first symptom of an undiagnosed renal cell carcinoma," ...
She had undergone a right radical nephrectomy for pT2N0M0, Fuhrmans grade 2, clear cell renal cell carcinoma 4 months ago. ... Metastatic Renal Cell Carcinoma Change Vascularity. Takeshi Azuma, Yukihide Matayoshi, Yohsuke Sato, Yujiro Sato, and Yasushi ... I. N. Zama, T. E. Hutson, P. Elson et al., "Sunitinib rechallenge in metastatic renal cell carcinoma patients," Cancer, vol. ... Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a ...
Advanced Renal Cell Carcinoma (RCC) cannot be cured by surgery alone. Its resillience to irradiation and chemotherapy demands a ... Cell Proliferation and Cellular Heterogeneity in Renal Cell Carcinoma. * Front Matter Pages 35-35 ... T-Cell Activation by Bispecific Monoclonal Antibodies for Lysis of Renal Cell Carcinoma In Vitro ... 31P NMR Spectroscopy of Human Tumor Cells In Vitro and In Vivo: Prospects for Applications to Renal Cell Carcinoma ...
The therapeutic approach for renal cell carcinoma is guided by the probability of cure, which i... ... and recommendations for patients with predominantly clear cell carcinoma and those with predominantly non-clear cell carcinoma ... Treatment protocols for renal cell carcinoma are provided below, including treatment of localized and advanced disease ... encoded search term (Renal Cell Carcinoma Treatment Protocols) and Renal Cell Carcinoma Treatment Protocols What to Read Next ...
Stage 4 Renal Cell Carcinoma: Treatment Options and Prognosis www.healthline.com/health/rcc/stage-4-renal-cell-carcinoma- ... ccr.cancer.gov/news/article/understanding-papillary-renal-cell-carcinoma. Renal cell carcinoma (RCC), the most common form of ... cme.healio.com/oncologyce/renal-cell-carcinoma. Renal Cell Carcinoma These continuing medical education activities are provided ... connect.mayoclinic.org/discussion/renal-cell-carcinoma-1. My friend now only recognized that she have left renal carcinoma.it ...
Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal ... Renal Cell Carcinoma Epidemiology. Read More Renal Cell Carcinoma Symptoms. Read More Renal Cell Carcinoma Diagnosis. Read More ... What is Renal Cell Carcinoma? Renal cell carcinoma, also called hypernephroma, is a cancer of the kidneys that forms in the ... Renal Cell Carcinoma. Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining ...
Renal cell carcinoma, NOS, Renal Cell Cancer, Renal Cell Carcinoma, Renal Cell Carcinoma, Stage Unspecified, Renal Cell ... renal cell carcinoma renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the ... Adenocarcinoma, CARCINOMA, RENAL CELL, MALIGNANT, carcinoma, renal cell (en); Cancer del rinón, Cáncer de riñón, Cancer de ... renal cell carcinoma (en); سرطانة الخلية الكلوية (ar); 肾细胞癌 (zh-hans); Rak bubrega (bs) renal carcinoma that has material basis ...
... (RCC) is curable only in patients presenting with resectable, early-stage disease. Advanced local or ... Renal arteriograms are occasionally still performed during evaluation of a solid renal mass. Renal-cell carcinoma ... Swanson DA, Wallace S: Surgery of metastatic renal cell carcinoma and use of renal infarction. Semin Surg Oncol 4:124â 128, ... Kovacs G, Frisch S: Clonal chromosome abnormalities in tumor cells from patients with sporadic renal cell carcinomas. Cancer ...
... , Kidney Cancer, Renal Cancer, Renal Cell Adenocarcinoma, Clear Cell Adenocarcinoma of Kidney, Papillary ... renal cell, adenocarcinoma; renal cell, renal cell; adenocarcinoma, renal cell; carcinoma, Renal Cell Carcinoma, Renal Cell ... Renal cell carcinoma NOS, renal cell carcinoma (diagnosis), renal cell carcinoma, renal adenocarcinoma, Carcinoma, Renal Cell [ ... RENAL CELL ADENOCARCINOMA, Renal cell carcinoma, NOS, Renal cell carcinoma (disorder), Renal cell carcinoma, Renal cell ...
Sorafenib in advanced clear-cell renal-cell carcinoma.. Escudier B1, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, ... in patients with advanced clear-cell renal-cell carcinoma.. METHODS: From November 2003 to March 2005, we randomly assigned 903 ... treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom ... What are the indications for sorafenib treatment in patients with renal cell carcinoma? [Nat Clin Pract Oncol. 2007] ...
Inc.) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ... Inc.) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ...
This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and ... Renal Cell Carcinoma. Book Subtitle. Molecular Features and Treatment Updates. Editors. * Mototsugu Oya ... Renal Cell Carcinoma. Molecular Features and Treatment Updates. Editors: Oya, Mototsugu (Ed.) ... This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and ...
Learn about the staging criteria and get the facts on stage 4 renal cell carcinoma, the most advanced stage of the disease. ... Renal cell carcinoma (RCC) is the most common type of kidney cancer. The earlier its detected, the greater your chance for ... Understanding renal cell carcinoma (RCC). Renal cell carcinoma (RCC) is a type of cancer that affects the cells of the kidney. ... More in Fight for the Future with Renal Cell Carcinoma. *. 7 Tips to Stay on Track with Your At-Home Renal Cell Carcinoma Care ...
Male and female adults with metastatic renal cell carcinoma. *Patients will have tumors that bear a clear cell component that ... Brivanib Metastatic Renal Cell Carcinoma. The safety and scientific validity of this study is the responsibility of the study ... Brivanib Metastatic Renal Cell Carcinoma Official Title ICMJE Brivanib (BMS-582664, Brivanib Alaninate) in Treatment of ... This study will evaluate the safety and effectiveness of brivanib in renal cell carcinoma, and explore the activity of this ...
Reviews and ratings for Votrient when used in the treatment of renal cell carcinoma. 53 reviews submitted with a 8.2 average ... After 8 months of CTs, I had to go and get a biopsy and it proved 2 clear and 2 renal cell carcinoma had appeared between my ... Bilateral Renal cell carcinoma. Left total nephectomy and partial right. Small spot on liver at that time. Remaining tumors on ... User Reviews for Votrient to treat Renal Cell Carcinoma. Votrient has an average rating of 8.2 out of 10 from a total of 47 ...
Pfizer is currently recruiting for the NCT02315755 Renal Cell Carcinoma Cancer trial. Review trial description, criteria and ...
  • The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial. (renalandurologynews.com)
  • Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not. (renalandurologynews.com)
  • Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma. (renalandurologynews.com)
  • If left untreated, RCC can become advanced or metastatic, meaning the cancer cells have spread to other areas of the body. (novartis.com)
  • Excruciating, sharp, bandlike back pain may be an early warning for spinal cord compression due to metastatic renal cell carcinoma and should not be ignored. (medscape.com)
  • Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. (medscape.com)
  • Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. (medscape.com)
  • More than 80% of patients with metastatic renal cell carcinoma remained alive without disease progression 3 years after image-guided local ablation of tumors, a retrospective study showed. (medpagetoday.com)
  • A mammalian target of rapamycin (mTOR) inhibitor failed to improve outcomes in metastatic renal cell carcinoma (RCC) as compared with other therapeutic options, according to two randomized trials. (medpagetoday.com)
  • Two small-molecule inhibitors proved comparable as first-line therapy for metastatic renal-cell carcinoma (RCC), results of a large randomized trial showed. (medpagetoday.com)
  • SILVER SPRING, Md. -- An FDA advisory committee voiced near unanimous disapproval for a novel advanced renal cell carcinoma drug and a drug-device combo to treat unresectable ocular melanoma that is metastatic to the liver. (medpagetoday.com)
  • Metastatic growth of renal cell carcinoma did not increase after completion of treatment with sunitinib (Sutent), alleviating concerns that had arisen in recent animal studies, an analysis of trial findings showed. (medpagetoday.com)
  • VIENNA -- Metastatic renal cell carcinoma responded about as well to the oral targeted agent pazopanib (Votrient) as to oral sunitinib (Sutent), researchers said here. (medpagetoday.com)
  • Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). (hindawi.com)
  • Recently new molecular targeted agents were approved for metastatic renal cell carcinoma (mRCC) [ 1 ]. (hindawi.com)
  • Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma. (news-medical.net)
  • Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease. (news-medical.net)
  • This is a phase II study of an investigational agent, brivanib, in patients with refractory metastatic renal cell carcinoma. (clinicaltrials.gov)
  • Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs. (nih.gov)
  • Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) are safe and effective after treatment with a programmed cell death 1 (PD-1) inhibitor in patients with metastatic renal cell carcinoma. (medworm.com)
  • The IMmotion 151 randomized phase 3 trial of atezolizumab plus bevacizumab was also superior over sunitinib in previously untreated metastatic renal cell carcinoma. (urotoday.com)
  • Given the movement of immuno-oncology agents from second-line to first-line metastatic renal cell carcinoma patients, with outstanding efficacy and tolerability, it is logical to move even earlier into the adjuvant setting for those patients with high-risk features after nephrectomy. (urotoday.com)
  • For many patients diagnosed with metastatic renal cell carcinoma, sunitinib alone is not inferior to surgery followed by sunitinib. (cancernetwork.com)
  • The median survival for patients with metastatic disease from renal cell carcinoma is 13 months, but, in patients with gastric metastasis, the clinical course appears to be unpredictable, and they could die within a few weeks because of the high frequency of concomitant tumour involvement of other organs (5). (isciii.es)
  • 3. Pollheimer MJ, Hinterleitner T A, Pollheimer VS, Schlemmer A, Langner C. Renal cell carcinoma metastatic to the stomach: single-centre experience and literature review. (isciii.es)
  • Unusual gastric and pancreatic metastatic renal cell carcinoma presentation 10 years after surgery and immunotherapy: A case report and a review of literature. (isciii.es)
  • Biopsy proven clear cell kidney cancer with metastatic disease. (clinicaltrials.gov)
  • Renal cell carcinoma (kidney cancer) is among the 10 most common cancers in both men and women, with 15-25 percent of patients having metastatic renal cell carcinoma (mRCC) where the cancer has spread to other parts of the body. (accc-cancer.org)
  • WOODCLIFF LAKE, N.J. , July 28, 2015 /PRNewswire/ -- Eisai Inc. announced today the U.S. Food and Drug Administration (FDA) granted lenvatinib, the company's multiple receptor tyrosine kinase inhibitor, Breakthrough Therapy designation for the investigational use in patients with advanced or metastatic renal cell carcinoma (RCC) who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy. (prnewswire.com)
  • We are excited and honored that the FDA has granted Breakthrough Therapy designation to lenvatinib for patients with metastatic renal cell carcinoma,' said Kenichi Nomoto , Ph.D., President, Oncology Product Creation Unit at Eisai Inc. 'We look forward to working closely with the FDA to expedite this clinical program and hope to offer an important additional treatment option to patients in need. (prnewswire.com)
  • Lenvatinib is not indicated for patients with metastatic renal cell carcinoma. (prnewswire.com)
  • LENVIMA (lenvatinib) has not been approved for patients with metastatic renal cell carcinoma. (prnewswire.com)
  • Choueiri, T.K. & Motzer, R.J. Systemic therapy for metastatic renal-cell carcinoma. (nature.com)
  • MIAMI - An analysis of patients with metastatic renal cell carcinoma treated during the targeted therapy era showed those with private insurance survived significantly longer than those with no insurance or government insurance, according to study results presented at International Kidney Cancer Symposium. (healio.com)
  • This survival disparity was more significant [among] patients aged younger than 65 years, suggesting insurance status determined access to metastatic renal cell carcinoma treatment," Yu-Wei Chen, MD, MS, of Cleveland Clinic Taussig Cancer Institute, and colleagues wrote. (healio.com)
  • Treatment costs for metastatic renal cell carcinoma have increased with the development of targeted therapy, and this may affect access to care, according to study background. (healio.com)
  • Chen and colleagues assessed the effect of insurance status on receipt of treatment and survival among patients with metastatic renal cell carcinoma. (healio.com)
  • Researchers used the National Cancer Data Base to identify patients diagnosed with metastatic renal cell carcinoma from 2006 to 2013. (healio.com)
  • The association between insurance status and survival in metastatic renal cell carcinoma in the United States. (healio.com)
  • It can extend into the renal veins where it forms tumoural thrombi not necessarily metastatic, but witch may disseminate in the adrenal glands, the congener kidney or remotely in the lungs, skeleton, liver, colon, diaphragm or mammary gland (particularly the clear-cell type). (scielo.br)
  • Clear cell, papillary and chromophobe are the most common histological subtypes of RCC, and their preoperative radiological characterization, either followed or not by confirmatory percutaneous biopsy, may be particularly useful in cases of poor surgical condition, metastatic disease, central mass in a solitary kidney, and in patients eligible for molecular targeted therapy. (scielo.br)
  • What are the side effects of chemotherapy when you get it to treat metastatic renal cell carcinoma? (webmd.com)
  • This study will evaluate everolimus as second-line therapy in patients with metastatic renal cell carcinoma. (clinicaltrials.gov)
  • The study included patients across International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic risk groups. (prnewswire.com)
  • Incidence, mortality, and the incidence of metastatic disease at first presentation for cancer of the kidney and renal pelvis. (aafp.org)
  • Despite the approval of several targeted therapies by entities such as the Food and Drug Administration, the European Medicines Agency and the Pharmaceuticals and Medical Devices Agency, the survival rate among patients with metastatic renal cell carcinoma has plateaued. (curetoday.com)
  • We present a case of sarcomatoid renal cell carcinoma with multiple sclerotic skeletal metastatic lesions. (semanticscholar.org)
  • When compared to conventional clear cell renal cell carcinoma (RCC), the prognosis of non-metastatic PRCC is more favorable, whereas a relatively worse outcome was reported in patients with metastatic disease. (wikipedia.org)
  • Clear-cell carcinoma, the most common-cell type, is present in more than 90% of tumors. (cancernetwork.com)
  • Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. (springer.com)
  • The study built upon prior research that showed a high response rate and improved progression-free survival and overall survival in patients with clear-cell RCC who used sunitinib to interfere with the growth of cancers cells, either slowing or stopping the development of tumors. (medindia.net)
  • Renal tumors are often detected incidentally during a computed tomography scan of the abdomen or chest that was ordered for unrelated symptoms. (aafp.org)
  • Surgery, although the therapy of choice for locally advanced renal tumors, is still controversial as the treatment for metastases. (waterstones.com)
  • These tumors arose from proximal tubule epithelial cells and shared molecular markers and mRNA expression profiles with human ccRCC. (nature.com)
  • Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. (nature.com)
  • The number of renal cell carcinoma cases incidentally discovered during routine medical check-ups has increased in recent years, and in our study, such incidental tumors accounted for 65.3% of all cases. (spandidos-publications.com)
  • Tumors arising in the renal pelvis may seed the ureters. (renalandurologynews.com)
  • Based on morphologic features defined in the WHO International Histological Classification of Kidney Tumors, RCC can be divided into clear cell (conventional), papillary (chromophil), chromophobe, collecting duct, and unclassified subtypes ( 1 , 2 ). (aacrjournals.org)
  • Sutent was first approved in 2006 for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma. (empr.com)
  • Herein, we report B7-H1 expression by both renal cell carcinoma (RCC) tumors of the kidney and RCC tumor-infiltrating lymphocytes. (pnas.org)
  • In addition, our analysis of 196 clinical specimens reveals that patients harboring high intratumoral expression levels of B7-H1, contributed by tumor cells alone, lymphocytes alone, or tumor and/or lymphocytes combined, exhibit aggressive tumors and are at markedly increased risk of death from RCC. (pnas.org)
  • Due to the large number of tumors analyzed we could evaluate potential differences in expression patterns of cell cycle regulators between conventional, papillary, and chromophobe RCCs. (diva-portal.org)
  • Renal cell cancer (RCC) constitutes a group of epithelial tumors that are highly heterogeneous with respect to morphology and clinical behaviour. (atlasgeneticsoncology.org)
  • This might be explained by the fact that common RCC arises from mature renal tubular cells, whereas papillary tumors are from embryonal origin. (atlasgeneticsoncology.org)
  • In former times it was believed that certain clear cell epithelial renal tumors are derived from ectopic adreno-cortical elements as expressed by Virchow and advocated by Grawitz. (atlasgeneticsoncology.org)
  • This evidence is corroborated by animal experiments and observation of pre-stages and early stages of epithelial renal tumors in human kidneys. (atlasgeneticsoncology.org)
  • Papillary (or chromophilic) cell tumors (thought to arise from the proximal tubule) comprise 10-15% of RCC cases. (atlasgeneticsoncology.org)
  • However, the most common form of renal cancer deviates from this behavior and presents some defects in its metabolic network not present in the normal kidney and unseen in other tumors. (pnas.org)
  • Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes (tubules) in the kidney. (medlineplus.gov)
  • Renal cell carcinoma is the most common type of kidney cancer in adults. (medlineplus.gov)
  • Renal cell cancer treatment (PDQ) -- health professional version. (medlineplus.gov)
  • Once renal cell cancer has been diagnosed, its stage is then determined to indicate how far the cancer has progressed. (britannica.com)
  • This is then sent for analysis under the microscope to check for the presence of cancer cells. (news-medical.net)
  • Kidney cancer occurs when cancer cells form in the kidneys. (healthline.com)
  • Cryoablation is a procedure that involves the freezing of cancer cells. (healthline.com)
  • Targeted therapies, which are medications that target kidney cancer cells, may be used if the cancer has spread. (healthline.com)
  • Targeted therapies are drugs that target specific receptors or molecules along the cancer cell growth pathways that slow or halt cancer growth. (healthline.com)
  • Survival rates for renal cell carcinoma are sometimes based on the percentage of people who live at least five years after the cancer is discovered. (healthline.com)
  • Renal cell carcinoma occurs when cancer cells form in the tubules of the kidney. (healthline.com)
  • The renal cancer cells may metastasize (spread) to other areas of the body. (medicinenet.com)
  • however, it's likely that kidney cancer begins when kidney cells mutate or a person inherits certain genes. (medicinenet.com)
  • I kept thinking about a dear friend's father who had been diagnosed with renal cancer and died six months later. (sheknows.com)
  • Prospective evaluation of analgesic use and risk of renal cell cancer. (medscape.com)
  • Renal cell carcinoma is the 14th most common cancer worldwide, with the highest incidence rates in North America, Europe, and Australia. (prweb.com)
  • Skin cancer is the most common type of cancer in the United States, with Basal and Squamous Cell skin cancer being the most common carcinoma types. (reference.com)
  • Renal cell carcinoma (RCC), the most common form of kidney cancer in adults, is not a single disease but rather a collection of different tumor types driven by distinct genetic cha. (reference.com)
  • Renal cell carcinoma (RCC) is the most common type of kidney cancer. (reference.com)
  • Renal cell carcinoma is a type of kidney cancer that starts i. (reference.com)
  • Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products. (news-medical.net)
  • Renal cell carcinoma, also called hypernephroma, is a cancer of the kidneys that forms in the proximal convoluted tubule. (news-medical.net)
  • In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma. (news-medical.net)
  • New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become "addicted" to glucose could open up fresh approaches to therapy strategies for cancers with high levels of an amino acid transporter called solute carrier family 7 member 11 (SLC7A11). (news-medical.net)
  • An experimental drug already shown to be safe and help some patients with clear cell renal cell carcinoma, a deadly form of kidney cancer, effectively disables its molecular target. (news-medical.net)
  • Scientists at the MDC have discovered stem cells responsible for the most common form of kidney cancer. (news-medical.net)
  • Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. (springer.com)
  • Renal cell carcinoma (RCC) is a type of cancer that affects the cells of the kidney. (healthline.com)
  • In this instance, the cancer cells may or may not have spread into other organs in the body. (healthline.com)
  • Immunotherapy is a treatment technique that aims to stimulate the immune system to attack cancer cells. (healthline.com)
  • Targeted therapy for RCC means using drugs that specifically target cancer cells. (healthline.com)
  • This growth factor stimulates the growth of cancer cells. (healthline.com)
  • It involves using a drug or combination of drugs to kill cancer cells. (healthline.com)
  • B. van der Werf-Messing, R.O. van der Heul, and R. Ch. Ledeboer, Renal cell carcinoma trial, Cancer Clin. (springer.com)
  • J. Ammon, J.H. Karstens, G. Durben, and K.H. Barth, Carcinoma of renal parenchyma, renal pelvis and ureter - radiological diagnosis and treatment planning, Cancer Treat. (springer.com)
  • University of Texas M. D. Anderson Cancer Center) Receptors for leptin, a protein hormone, may be associated with tumor recurrence in patients with renal cell carcinoma (RCC), providing further understanding about molecular links between obesity and RCC tumor formation and prognosis, according to a study at The University of Texas MD Anderson Cancer Center. (medworm.com)
  • Nivolumab is now approved in Europe for both nonsquamous- and squamous-type non-small-cell lung cancer, as well as for use in renal cell carcinoma. (medworm.com)
  • Renal cell carcinoma is the most common type of kidney cancer. (copays.org)
  • Albany, NY -- ( SBWIRE ) -- 08/07/2017 -- Renal cell carcinoma, also known as adenocarcinoma, refers to the cancer of kidneys in which malignant cells are found in the renal tubules. (sbwire.com)
  • Among the types of kidney cancer, renal cell carcinoma is highly prevalent and accounts for 80-90% of the total cases as opposed transitional cell carcinoma which constitutes 5 -10% The renal cell carcinoma market is expected to develop at a decent rate due to the increased incidence reported worldwide. (sbwire.com)
  • Chemotherapy is not effective in renal cell cancer and results in multiple side effects such as nausea & vomiting and weight & hair loss. (sbwire.com)
  • Immunotherapy is a broad category of anti-cancer therapies that uses the body's immune system to fight cancer cells. (cancertutor.com)
  • The most common type of cancer in the kidneys is renal cell carcinoma which starts in the area of the kidney where urine is created. (cancertutor.com)
  • Bladder cancer begins when cells in the urinary bladder start to grow uncontrollably. (cancertutor.com)
  • As more cancer cells develop, they form a tumor. (cancertutor.com)
  • There are two major kinds of kidney cancer: Renal Cell Carcinoma (RCC) and Urothelial Cell Carcinoma (UCC). (cancertutor.com)
  • Cancer Network presents exclusive coverage on renal cell carcinoma from the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. (cancernetwork.com)
  • New findings shows that a non-clear cell form of kidney cancer known as papillary RCC, which accounts for 12 percent of all RCC, responds differently to sunitinib - a standard frontline treatment for RCC. (medindia.net)
  • The terms clear- and non-clear cell refer to the general appearance of the cancer cells under a microscope. (medindia.net)
  • With clear-cell RCC, there is a lot of data," said Fox Chase Cancer Center medical oncologist Elizabeth R. Plimack, M.D., M.S., who led the study while at University of Texas MD Anderson Cancer Center and will report the results at the 46th Annual Meeting of the American Society of Clinical Oncology on Monday, June 7. (medindia.net)
  • Because data on the behavior of non-clear cell kidney cancer is lacking, the disease has been treated similarly to clear cell. (medindia.net)
  • Now that we're taking a hard look at how sunitinib works on non-clear cell kidney cancer, we're seeing a lot of differences between the two diseases," says Plimack. (medindia.net)
  • We really need to investigate papillary renal cell carcinoma separately from clear-cell renal cell carcinoma and aggressively pursue new agents for this rare but distinct subtype of renal cell cancer," says Plimack. (medindia.net)
  • Renal cell carcinoma is kidney cancer that affects the lining of the kidney tubules. (medindia.net)
  • Kidney cancer is one of the 10 most common cancers in the United States with 90% being attributed to renal cell carcinoma. (aafp.org)
  • 2 Death attributed to renal cell carcinoma accounted for 2% of all cancer deaths or approximately 14,000 persons in 2016. (aafp.org)
  • 5 , 7 - 9 The International Agency for Research on Cancer labels trichloroethylene as carcinogenic to humans and specifically associates it with renal cancer. (aafp.org)
  • Renal cell carcinoma, also known by a gurnistical tumor, is the most common form of kidney cancer arising from the renal tubule. (dailystrength.org)
  • The immune system contains many different types of "cells," however, only a handful of these white blood cells actually kill cancer cells. (cancertutor.com)
  • It should be the intent of a person with cancer to focus on treatments that quickly increase the count of the cancer-killing white blood cells. (cancertutor.com)
  • People with only a few months to live should definitely take immune system building products - and focus more on the nutrients, foods and products that kill cancer cells directly, such as the Grape Cure , Noni Juice, Essiac Tea , etc. or revert the cancer cells into normal cells. (cancertutor.com)
  • Carfilzomib is designed to block cancer cells from repairing themselves. (clinicaltrials.gov)
  • If the cancer cells cannot repair themselves, this may cause them to die. (clinicaltrials.gov)
  • As recent developments show, new strategies for immunotherapy of renal cell carcinoma represent a modest advance over traditional approaches in the treatment of this cancer, such as chemo- and radiotherapy. (waterstones.com)
  • This article focuses on renal cell carcinoma and the term 'kidney cancer' will be used to refer to RCC. (naturalcures.com)
  • In a malignant tumour the cancer cells have the ability to spread beyond the original area of the body. (naturalcures.com)
  • Sometimes cells break away from the original (primary) cancer. (naturalcures.com)
  • When the cancer cells reach a new area they may go on dividing and form a new tumour. (naturalcures.com)
  • Renal cell carcinoma (RCC), also known as kidney cancer or renal adenocarcinoma, is the most common type of kidney cancer in adults, occurring at an average age of 64 years. (reportlinker.com)
  • It accounts for approximately 3% of adult malignancies and 90% to 95% of malignant neoplasm (cancer cells) involving the kidneys. (reportlinker.com)
  • Renal cell carcinoma is the ninth leading cause of cancer death in the US. (reportlinker.com)
  • Renal cell cancer (RCC) accounts for ~3% of human malignancies and its incidence appears to be rising. (genome.jp)
  • Although most cases of RCC seem to occur sporadically, an inherited predisposition to renal cancer accounts for 1-4% of cases. (genome.jp)
  • ACCC's Improving Quality Care in Renal Cell Carcinoma project seeks to improve the quality of care for renal cell carcinoma patients treated at community cancer programs. (accc-cancer.org)
  • Genitourinary cancer expert Robert Motzer discusses new treatment options for patients with advanced renal cell carcinoma. (mskcc.org)
  • Von Hippel-Lindau ( VHL ) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. (nature.com)
  • Cancer Cell 1 , 459-468 (2002). (nature.com)
  • MiRNA can control the important cancer-related genes and participate in the tumor cell proliferation, apoptosis, invasion and angiogenesis. (knowcancer.com)
  • Physicians treating advanced renal cell carcinoma have had few options to help achieve the goal of improved survival," Robert J. Motzer , MD , medical oncologist and Jack and Dorothy Byrne chair in clinical oncology at Memorial Sloan Kettering Cancer Center, said in a company-issued press release. (healio.com)
  • MK-3475 is an investigational, highly selective anti-PD-1 immunotherapy designed to restore the natural ability of the immune system to recognize and target cancer cells by selectively achieving dual ligand blockade (PD-L1 and PD-L2) of the PD-1 protein. (businesswire.com)
  • By blocking PD-1, MK-3475 enables activation of the immune system's T-cells that target cancer by essentially releasing a brake on the immune system. (businesswire.com)
  • His doctor diagnosed him with renal cell carcinoma, the most common type of kidney cancer . (mdanderson.org)
  • Renal cell carcinoma is a highly malignant cancer that would benefit from non-invasive innovative markers providing early diagnosis and recurrence detection. (mdpi.com)
  • Renal cell carcinoma (RCC) is the seventh most common histological type of cancer in the Western world and has shown a sustained increase in its prevalence. (scielo.br)
  • New strategies recently developed for treating renal cancer, such as cryo and radiofrequency ablation, molecularly targeted therapy and active surveillance also require appropriate preoperative characterization of renal masses. (scielo.br)
  • Renal cell carcinomas (RCCs) are the seventh most common histological type of cancer in the Western world and have maintained an increasing prevalence ( 1 , 2 ) , representing 1% to 3% of all malignant visceral neoplasms. (scielo.br)
  • It's important for us to understand that the modern therapeutics of renal cell cancer are predicated on what we've learned about the molecular makeup of the cancer, particularly driven by pathways such as angiogenesis and also the MTOR pathway and then an altered immune system in most renal cell cancers that is targetable. (curetoday.com)
  • The other issue is this: Do markers in renal cancer tissue help us with treatment at the moment? (curetoday.com)
  • Basing on the symptoms of kidney cancer, the patient's condition and the results of preliminary tests, the doctor chooses one or another method for diagnosing renal cell carcinoma to form the most objective image. (rxmed.com)
  • The tumor is subjected to alternating freezing and thawing, which eventually leads to the death of cancer cells. (rxmed.com)
  • Inadequate, inappropriate, or inhibitory T cell costimulatory pathway signaling have all been shown to restrict a host's ability to generate productive immune responses against cancer. (pnas.org)
  • Kidney cancer expert Robert Motzer (center) led two clinical trials that showed promising results for patients with advanced renal cell carcinoma. (mskcc.org)
  • Two drugs have shown in clinical trials led by Memorial Sloan Kettering medical oncologist and kidney cancer expert Robert J. Motzer that they improve outcomes in patients with advanced renal cell carcinoma (RCC). (mskcc.org)
  • Renal cell carcinoma is the most common form of kidney cancer. (mskcc.org)
  • Renal cell carcinoma is a disease that is crying out for new and novel treatment strategies, and this trial has produced practice-changing results in a cancer that is highly resistant to other therapies. (mskcc.org)
  • There is a high incidence of kidney cancer in Europe , and for the most common type, renal cell carcinoma, we continue to need additional treatment options, particularly for patients with advanced disease, where outcomes are poorest,' said Professor James Larkin , Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and Professor at the Institute of Cancer Research (ICR). (prnewswire.com)
  • The European Commission approval of BAVENCIO in combination with axitinib has the potential to bring even more patients with advanced renal cell carcinoma a new first-line treatment, and it allows us to continue to deliver on our more than decade-long passion to do more for patients with kidney cancer,' said Andy Schmeltz , Global President, Pfizer Oncology. (prnewswire.com)
  • It was only a few months following the vasculitis that I was diagnosed with renal cell cancer. (cancerguide.org)
  • I also know of at least five other individuals with a similar medical history of renal cell cancer and Prozac reaction. (cancerguide.org)
  • Remarkably, as pointed out in Gray and Harris's review of renal cell carcinoma in this issue of American Family Physician , 4 some version of this story is now responsible for more than one-half of kidney cancer diagnoses. (aafp.org)
  • Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. (wikipedia.org)
  • The combination use of Keytruda plus Inlyta significantly improved survival outcomes among patients with previously untreated advanced renal cell carcinoma - the most common type of kidney cancer. (curetoday.com)
  • The researchers noted the benefit found with Keytruda in combination with Inlyta was also observed across risk groups (favorable, intermediate and poor risk) and regardless of PD-L1 expression - a type of protein found on cancer cells that helps to determine treatment options. (curetoday.com)
  • Indeed, many common oncogenic signaling pathways have been implicated in the emergence of specific metabolic features in cancer cells that have been associated with both survival and sustained abnormal proliferation rate ( 2 ⇓ ⇓ - 5 ). (pnas.org)
  • Only recently a systemic study using transcriptional regulation has attempted to rule out the possibility that other metabolic processes in the network may achieve equal importance in cancer cells ( 6 ), and the idea that all cancer cells display a unique metabolic phenotype has spurred disputes that mainly highlighted a lack of comprehensive evidence ( 7 ). (pnas.org)
  • Taken together, we contend that only a systems perspective may help to elucidate the extent to which different cancer cells coordinate their metabolic activity. (pnas.org)
  • As with other types of renal cell cancer, most cases of PRCC are discovered incidentally without showing specific signs or symptoms of cancer. (wikipedia.org)
  • Type 1 PRCC, also known as a renal tumor caused by a genetic predisposition of hereditary papillary renal cancer syndrome, compromises approximately 25% of all PRCCs. (wikipedia.org)
  • Regarding hereditary conditions, patients with hereditary papillary renal cancer syndrome showed a greater risk of type 1 PRCC, whereas those with hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome have an increased risk of type 2 PRCC. (wikipedia.org)
  • The most frequent histological subtypes include clear cell renal cell carcinomas (ccRCC), papillary renal cell carcinomas (pRCC), and chromophobe renal cell carcinomas (crRCC) ( Figure 1 ). (scielo.br)
  • Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. (aacrjournals.org)
  • Other genetically linked conditions also increase the risk of RCC, including hereditary papillary renal carcinoma, hereditary leiomyomatosis, Birt-Hogg-Dube syndrome, hyperparathyroidism-jaw tumor syndrome, familial papillary thyroid carcinoma, von Hippel-Lindau disease and sickle cell disease. (wikipedia.org)
  • Papillary renal cell carcinoma (PRCC) is a malignant, heterogeneous tumor originating from renal tubular epithelial cells of the kidney, which comprises approximately 10-15% of all kidney neoplasms. (wikipedia.org)
  • it represents a special subtype of renal cell carcinoma (RCC) associated with a low nuclear grade and stage and an excellent prognosis regardless of tumor size. (medscape.com)
  • Renal cell carcinoma, or RCC, develops in the lining of the kidney's tubes and grows into a mass or tumor. (novartis.com)
  • The therapeutic approach for renal cell carcinoma is guided by the probability of cure, which is related directly to the stage or degree of tumor dissemination. (medscape.com)
  • Some melanomas, sarcomas and renal cell carcinomas, but not all, have been found to respond dramatically to new drugs called immune checkpoint blockers, which exploit the body's known capability to mount an immune response against the foreign antigen-bearing tumor cells. (news-medical.net)
  • Three tumor suppressor genes appear to reside on 3p: the VHL gene at 3p25-26 and two more proximal genes, at 3p14 (proposed name, nonpapillary renal carcinoma gene, or NRC-1 ) and 3p21 [15,18-22]. (cancernetwork.com)
  • We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma. (nih.gov)
  • Delicate capillary often ruptures during surgical manipulation, resulting in formation of "blood lakes" within tumor cell nests. (auanet.org)
  • Receptors for leptin, a protein hormone, may be associated with tumor recurrence in patients with renal cell carcinoma (RCC), providing further understanding about molecular links between obesity and RCC tumor formation and prognosis, according to a study. (medworm.com)
  • A triphasic renal CT with IV contrast ordered nine months later to confirm the angiomyolipoma revealed a fat-poor, hypovascular tumor that enhanced from 34 to 70 Hounsfield units. (empr.com)
  • This 64-year-old female patient, was referred to our clinic with an enlarging right renal tumor. (empr.com)
  • Clear cell renal cell carcinomas (ccRCCs) frequently exhibit inactivation of the von Hippel-Lindau tumor-suppressor gene, VHL , and often harbor multiple copy-number alterations in genes that regulate cell cycle progression. (nature.com)
  • In this study, renal cell carcinoma(RCC) related miRNA and the target genes of related miRNA will be examined,and the relationship between RCC related miRNA and the RCC pathological types, TNM (tumor-nodes-metastasis) stages and prognosis will be analyzed. (knowcancer.com)
  • Circulating tumor cells are a particularly promising marker of tumor invasion that could be used to improve the management of patients with RCC. (mdpi.com)
  • Paterlini-Bréchot, P. Circulating Tumor Cells for the Management of Renal Cell Carcinoma. (mdpi.com)
  • Renal cell carcinomas (RCC) are primary malignant adenocarcinomas derived from the renal tubular epithelium and are the most common malignant renal tumor. (researchandmarkets.com)
  • Aspectos histológicos descritos neste indivíduo caracterizam carcinoma de células renais, também conhecido como adenocarcinoma renal, hipernefroma ou, na literatura mais antiga, como tumor Grawitz. (scielo.br)
  • However, despite its minimum invasiveness, percutaneous biopsy involves risks and limitations and currently it is only indicated in cases where a renal tumor cannot be radiologically characterized or in specific clinical situations. (scielo.br)
  • We may end up in a situation where to give certain therapies we need to have a marker to do that, such as PD-L1 expression or elevation in the tumor or tumor infiltrating immune cells. (curetoday.com)
  • PRCC is histologically characterized by the presence of fibrovascular cores with tumor cells arranged in a papillary configuration. (aacrjournals.org)
  • Type 2 is characterized by the presence of large tumor cells with eosinophilic cytoplasm and pseudostratification. (aacrjournals.org)
  • The most effective way to treat renal cell carcinoma is surgical removal of the tumor. (rxmed.com)
  • In contrast, aberrant expression of B7-H1 by tumor cells has been implicated in impairment of T cell function and survival, resulting in defective host antitumoral immunity. (pnas.org)
  • In addition, aberrant tumor cell B7-H1 expression has been described in a number of human malignancies ( 2 , 3 ). (pnas.org)
  • B7-H1 expressed by tumor cells has been shown to enhance apoptosis of activated tumor-specific T cells in vitro ( 2 ). (pnas.org)
  • However, evidence that tumor-associated B7-H1, or any other T cell costimulatory molecule, facilitates solid tumor progression in the clinical setting is lacking. (pnas.org)
  • In contrast, favorable treatment responses have been elicited in subsets of RCC patients receiving cytokine-based immunotherapy ( 11 ), T cell adoptive immunotherapy ( 12 ), or vaccination with a variety of autologous tumor cell preparations ( 13 ). (pnas.org)
  • RCC is the most common malignant tumor arising in the kidney and accounts for 2% of all new cancers diagnosed, representing 85% all primary renal neoplasms in adults. (atlasgeneticsoncology.org)
  • Tumor cells express antigens of the proximal tubule. (atlasgeneticsoncology.org)
  • The adenomas tend to beige- to white colored small tumor masses whereas the carcinomas show an extensive greasy-brown colored central necrosis resulting from consecutive hemorrhages. (atlasgeneticsoncology.org)
  • The tumor cells exhibit centrally located small nuclei and the cytoplasm is contains few organelles only, especially endoplasmatic reticulum. (atlasgeneticsoncology.org)
  • As a rule the tumor cells are arranged in a (tubulo) papillary architecture. (atlasgeneticsoncology.org)
  • In 2014, PRCC was first acknowledged as a renal tumor subtype by the World Health Organization (WHO) considering its distinct genetic, molecular and histologic characteristics. (wikipedia.org)
  • Partial nephrectomy was associated with decreased odds of death versus radical nephrectomy among patients with cT1b but not cT2 renal cell carcinoma. (renalandurologynews.com)
  • Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. (medscape.com)
  • She had undergone a right radical nephrectomy for pT2N0M0, Fuhrman's grade 2, clear cell renal cell carcinoma 4 months ago. (hindawi.com)
  • On November 16, 2017, the Food and Drug Administration approved sunitinib malate (Sutent, Pfizer Inc.) for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy. (fda.gov)
  • in 2007, renal clear cell carcinoma with radical right nephrectomy (T3N0M0, stage III). (isciii.es)
  • Isolated gastric metastasis from renal cell carcinoma 10 years after radical nephrectomy. (isciii.es)
  • We investigated the clinicopathological features of 153 patients with renal cell carcinoma who underwent nephrectomy at our institute from April 1992 to August 2001 and evaluated the prognostic significance of various clinical and pathological factors. (spandidos-publications.com)
  • To evaluate the prevalence and the prognostic role of multifocality in a large multi-institutional series of patients who underwent radical or partial nephrectomy for renal cell carcinoma (RCC). (wiley.com)
  • Population exposure to computed tomography imaging and the risk of nephrectomy or renal ablation 2010-2014. (aafp.org)
  • According to a study by NCBI named "Racial Disparity in Renal Cell Carcinoma Patient Survival according to Demographic and Clinical Characteristics" published in 2012, the African population runs a comparatively higher risk of developing renal cell carcinoma. (sbwire.com)
  • Researchers found that people who ate lots of fruits and vegetables - more than 75 servings per month, or roughly three servings total per day - had the lowest risk of developing renal cell carcinoma. (medworm.com)
  • Renal cell carcinoma , a disease arising from malignant epithelial cells in the kidneys . (britannica.com)
  • If the imaging tests reveal a suspicious mass, your doctor will do a biopsy to check for malignant cells. (healthline.com)
  • Doctors can tell if a tumour is benign or malignant by removing a piece of tissue (biopsy) and examining a small sample of cells under a microscope. (naturalcures.com)
  • Renal cell carcinoma occurs when malignant cells a--re found in the lining of the tubules in the kidney. (prnewswire.com)
  • Renal carcinoma is a malignant formation formed in one or both kidneys. (rxmed.com)
  • Renal cell carcinoma is responsible for about 90 percent of kidney cancers in adults. (britannica.com)
  • Two rare disorders, tuberous sclerosis and von Hippel-Lindau syndrome, are often associated with renal cell cancers. (britannica.com)
  • As with many cancers, the symptoms of renal cell carcinoma are often associated with other disorders. (britannica.com)
  • Unlike many other cancers, renal cell carcinoma generally does not respond well to chemotherapy or radiation . (britannica.com)
  • Over 90 percent of kidney cancers are renal cell carcinomas (RCC), which start in the tubules of the kidneys. (healthline.com)
  • The remaining 10 percent of kidney cancers start in the renal pelvis in the center of the kidney, which is where urine collects. (healthline.com)
  • about 90% are predicted to be renal cell cancers. (medicinenet.com)
  • 1 Renal cell carcinoma accounts for 90% of all kidney cancers. (aafp.org)
  • UCC covers most of the other kidney cancers, but some kidney cancers are even squamous cell carcinomas, as just one example. (cancertutor.com)
  • The most common type is known as renal cell carcinoma (RCC), which accounts for about 90% of all kidney cancers. (naturalcures.com)
  • Ninety percent of bladder cancers are transitional cell carcinomas. (renalandurologynews.com)
  • K. Syrjänen and L. Hjelt, Grading of human renal adenocarcinoma, Scand. (springer.com)
  • It is also known as RCC, renal cell carcinoma, or renal cell adenocarcinoma. (copays.org)
  • Gastric metastasis of renal cell adenocarcinoma. (isciii.es)
  • Other types are squamous cell carcinoma, adenocarcinoma, and sarcoma. (renalandurologynews.com)
  • Histological aspects described in this individual characterize renal cell carcinoma, also known as renal adenocarcinoma, hypernephroma or, in older literature, Grawitz tumour. (scielo.br)
  • Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (nih.gov)
  • Bristol-Myers Squibb has obtained approval from the European Commission (EC) for its Opdivo (nivolumab) for previously treated advanced renal cell carcinoma (RCC). (medworm.com)
  • For example, in the CHECKMATE 025 trial, nivolumab was proven to be superior over everolimus for both progression-free survival (PFS) and overall survival (OS) in previously treated advanced renal cell carcinoma. (urotoday.com)
  • Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults. (nice.org.uk)
  • We show here that modeling these genetic alterations by combined deletion of Vhl , Trp53 and Rb1 specifically in renal epithelial cells in mice caused ccRCC. (nature.com)
  • Figure 1: Renal epithelial cell-specific co-deletion of Vhl , Trp53 and Rb1 permits the evolution of ccRCCs. (nature.com)
  • Transitional cell carcinoma arises from the epithelial layer found in the renal pelvis, ureter, or bladder. (renalandurologynews.com)
  • Epithelial renal cell carcinoma (RCC) accounts for the vast majority of renal malignancies in adults. (aacrjournals.org)
  • Sarcomatoid renal cell carcinoma is an example of epithelial--mesenchymal transition. (semanticscholar.org)
  • WHITEHOUSE STATION, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. (businesswire.com)
  • 1 Based on these results, the US FDA approved sunitinib for the adjuvant treatment of patients with high-risk renal cell carcinoma. (urotoday.com)
  • 4 The found the nivolumab and ipilimumab combination to be superior versus sunitinib in patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma. (urotoday.com)
  • Analysis from a phase III trial confirmed the prognostic value of a 16-gene recurrence score in patients with high-risk renal cell carcinoma undergoing adjuvant sunitinib therapy. (cancernetwork.com)
  • The FDA based this decision on data from 847 intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma from the randomized open-label CheckMate-214 trial, which compared the combination of nivolumab (Opdivo, Bristol-Myers Squibb) and ipilimumab (Yervoy, Bristol-Myers Squibb) with sunitinib (Sutent, Pfizer). (healio.com)
  • As the first treatment option to increase OS for subgroups of patients with advanced renal cell carcinoma compared to sunitinib, the Opdivo plus low-dose Yervoy combination helps deliver on that promise," Johanna Mercier, head of U.S. Commercial at Bristol-Myers Squibb, said in the press release. (healio.com)
  • Patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell (or with a component of clear cell) renal carcinoma that have previously progressed on or were intolerant to first-line therapy with sunitinib, sorafenib, pazopanib, axitinib, bevacizumab, or cytokine therapy. (clinicaltrials.gov)
  • Go to Clear Cell Renal Cell Carcinoma and Sarcomatoid and Rhabdoid Renal Cell Carcinoma for complete information on these topics. (medscape.com)
  • Sarcomatoid renal cell carcinoma (SRCC) is an aggressive variant of renal cell carcinoma. (semanticscholar.org)
  • Sarcomatoid renal cell carcinoma presenting in the oropharynx. (semanticscholar.org)
  • Four cases of sarcomatoid renal cell carcinoma]. (semanticscholar.org)
  • We herein report four cases of sarcomatoid renal cell carcinoma. (semanticscholar.org)
  • Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. (semanticscholar.org)
  • A case of sarcomatoid renal cell carcinoma is reported with light, immunohistochemical and electron microscopic findings. (semanticscholar.org)
  • Renal sarcoma and sarcomatoid renal cell carcinoma: CT and angiographic features. (semanticscholar.org)
  • Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. (semanticscholar.org)
  • Clear cell renal cell carcinoma (ccRCC) is characterized by inactivation of the von Hippel-Lindau tumour suppressor gene (VHL). (nih.gov)
  • VHL loss activates the HIF-2 transcription factor, and constitutive HIF-2 activity restores tumorigenesis in VHL-reconstituted ccRCC cells. (nih.gov)
  • PT2399 dissociated HIF-2 (an obligatory heterodimer of HIF-2α-HIF-1β) in human ccRCC cells and suppressed tumorigenesis in 56% (10 out of 18) of such lines. (nih.gov)
  • Following on from the blog last week, which described the identification of PBRM1 mutations in clear-cell RCC (ccRCC), other sequencing studies are also finding new genes that are mutated in ccRCC. (scienceblog.com)
  • On the other hand, clear cell renal cell carcinoma (ccRCC) strongly deviated in terms of metabolic gene expression changes, showing widespread down-regulation. (pnas.org)
  • In spite of advances in all fields of medical science, the prognosis of renal cell carcinoma has not improved during the last 25 years. (springer.com)
  • Generally, the earlier the renal cell carcinoma is found, the better the prognosis. (cancertutor.com)
  • Seventy-five percent to 80% of patients with advanced renal cell carcinoma have intermediate- or poor-risk disease, which historically is associated with a poor prognosis. (healio.com)
  • Although no laboratory test exists for diagnosing renal cell carcinoma, urinalysis may reveal blood in the urine, and a blood test may reveal anemia, elevated liver enzymes, or elevated calcium levels. (britannica.com)
  • Renal Cell Carcinoma Pipeline Analysis Report: 2017 includes list of pipeline of drugs in clinical development, and pipeline analysis by phase, indication sub-type, molecule type and company. (reportlinker.com)
  • According to this research, the total diagnosed incident cases of Advanced Renal Cell Carcinoma in the G8 countries were 69,429 in 2017. (researchandmarkets.com)
  • Along with their primary function, kidneys also account for hormones that control blood pressure and create red blood cells in bone marrow. (cancertutor.com)
  • In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma. (renalandurologynews.com)
  • Treatment plans for patients with advanced renal cell carcinoma (RCC) vary, but can often involve both surgery and medicine, and it is not uncommon for patients to be treated with more than one medicine or type of therapy. (novartis.com)
  • The US Food and Drug Administration (FDA) has approved the oral therapy cabozantinib ( Cabometyx , Exelixis) for the treatment of patients with advanced renal cell carcinoma (RCC) who have received previous antiangiogenic therapy. (medscape.com)
  • Advances in the treatment of renal disease. (medscape.com)
  • The FDA has rejected the oral VEGF receptor tyrosine kinase inhibitor tivozanib, intended for the treatment of renal cell carcinoma, according to the drug's developer. (medpagetoday.com)
  • Research finds that ablative techniques have widened the range of treatment options available to patients with renal cell carcinoma. (prweb.com)
  • Research published in the October issue of the American Journal of Roentgenology finds that the advent of ablative techniques has widened the range of treatment options available to patients with renal cell carcinoma (RCC). (prweb.com)
  • Treatment protocols for renal cell carcinoma are provided below, including treatment of localized and advanced disease and recommendations for patients with predominantly clear cell carcinoma and those with predominantly non-clear cell carcinoma. (medscape.com)
  • What are the indications for sorafenib treatment in patients with renal cell carcinoma? (nih.gov)
  • On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). (fda.gov)
  • Current results from treatment of renal cell carcinoma," 7th Proc. (springer.com)
  • This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. (nih.gov)
  • A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. (nih.gov)
  • Many big pharma companies are working in developing drugs for the treatment of renal cell carcinoma. (reportlinker.com)
  • This CME, CNE, and CPE-accredited educational program is designed to provide all members of the multidisciplinary care team knowledge and resources to successfully address practical issues and barriers faced in integration of immunotherapies into the treatment of renal cell carcinoma (RCC). (accc-cancer.org)
  • The purpose of this meeting is to educate urologists, oncologists, NPs and PAs on the evolving treatment landscape for advanced renal cell carcinoma. (regonline.com)
  • Checkpoint inhibitors for the treatment of renal cell carcinoma. (nature.com)
  • The FDA today approved the combination of nivolumab and ipilimumab for the treatment of intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma. (healio.com)
  • We retrospectively collected the data of 5378 patients who were surgically treated for RCC in 16 academic centres involved in the Surveillance and Treatment Update Renal Neoplasms (SATURN) project. (wiley.com)
  • This Phase I/II clinical trial is designed to evaluate the safety and efficacy of a combination of MK-3475 and pazopanib in treatment naïve patients with advanced renal cell carcinoma. (businesswire.com)
  • The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies. (mdanderson.org)
  • At MD Anderson , Travis began renal cell carcinoma treatment under Nizar Tannir, M.D. "He was very professional," Travis says. (mdanderson.org)
  • The report covers the detailed overview of Advanced Renal Cell Carcinoma explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns. (researchandmarkets.com)
  • The major drugs used for the treatment of renal cell carcinoma include Sutent, Nexavar, Votrient, Avastin and Inyta amongst others. (medindia.net)
  • The most recent drugs approved for the treatment of renal cell carcinoma is Bristol-Myers Squibb's Opdivo. (medindia.net)
  • The treatment of renal cell carcinoma is based on several common methods used alone or in a complex manner. (rxmed.com)
  • PFE ) today announced that the European Commission (EC) has approved BAVENCIO ® (avelumab) in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). (prnewswire.com)
  • We've seen a demonstrated efficacy benefit and safety and tolerability profile for avelumab in combination with axitinib across all prognostic risk groups in patients with advanced renal cell carcinoma, so today's approval in Europe brings an important option that can help healthcare professionals optimize treatment strategies across risk stratification. (prnewswire.com)
  • Renal cell carcinoma is characterized by susceptibility to both immunotherapeutic and antiangiogenic treatment approaches and resistance to cytotoxic chemotherapy," they wrote. (curetoday.com)
  • The significant overall survival advantage is particularly notable because it has not been achieved with first-line treatment of renal cell carcinoma with the use of anti-VEGF-based therapy administered alone or in combination. (curetoday.com)
  • The global renal cell carcinoma drugs market is anticipated to cross US$ 4.3 Billion mark by 2021. (medindia.net)
  • Sutent accounts for largest share of the global renal cell carcinoma drugs market in 2015, while, Votrient is projected to witness the strongest growth during the forecasting period. (medindia.net)
  • Global Renal Cell Carcinoma - Diagnosed Incident Cases to 2023 (8 Countries Covered)4. (medindia.net)
  • Global Renal Cell Carcinoma - Major Branded Drugs Product Profiles and Sales Analysis to 2021 (11 Brands Covered)6. (medindia.net)
  • Global Renal Cell Carcinoma Drugs - Pipeline Analysis (18 Drugs Covered)7. (medindia.net)
  • The report will help in developing business strategies by understanding the trends shaping and driving the global Renal cell carcinoma market. (beforeitsnews.com)
  • Identifying prevalent patient populations as well as risk factors in the global Renal cell carcinoma market will help to improve product design, pricing, and launch plans. (beforeitsnews.com)
  • Making some changes to the gut microbiome may improve outcomes with immune checkpoint inhibitors in renal cell carcinoma. (cancernetwork.com)
  • This approval demonstrates our commitment to bringing immuno-oncology treatments that may improve outcomes to a broader range of renal cell carcinoma patients. (healio.com)
  • The combination use of Keytruda (pembrolizumab) plus Inlyta (axitinib) significantly improved survival outcomes among patients with previously untreated advanced renal cell carcinoma (RCC), according to results from the KEYNOTE-426 trial published in The New England Journal of Medicine . (curetoday.com)
  • L.D. Sullivan, D.D. Westmore, and M.G. McLoughlin, Surgical management of renal cell carcinoma at the Vancouver General Hospital, a 20 years' review, Canad. (springer.com)
  • Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. (medscape.com)
  • In addition, multivariate analysis showed that regional lymph node metastasis, stage and histological type were independent prognostic factors for renal cell carcinoma. (spandidos-publications.com)
  • Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma. (biomedsearch.com)
  • The aim of this study was to evaluate the prognostic relevance of melanoma-associated antigen (MAGE) A9 in renal cell carcinoma (RCC). (biomedsearch.com)
  • Additional combinations of these immuno-oncology agents are currently being investigated in advanced renal cell carcinoma. (urotoday.com)
  • The tumour arises from the cells of the proximal renal tubular epithelium. (wikipedia.org)
  • Advanced Renal Cell Carcinoma Epidemiology Forecast - 2028' report delivers an in - depth understanding of the disease, historical & forecasted epidemiology of Advanced Renal Cell Carcinoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China. (researchandmarkets.com)
  • The report provides the segmentation of the disease epidemiology by type - specific cases and severity specific cases of Advanced Renal Cell Carcinoma in the G8 countries. (researchandmarkets.com)
  • The Report "Renal cell carcinoma - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Renal cell carcinoma in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). (beforeitsnews.com)
  • It includes 10 years epidemiology historical and forecasted data of Renal cell carcinoma prevalent or incident cases segmented by age, sex and subpopulations. (beforeitsnews.com)
  • The rising incidence of renal cell carcinoma and comparative lack of availability of effective therapies available point toward the scope of this market. (sbwire.com)
  • North America and Europe dominated the global market due to unhealthy lifestyles, obesity, and hypertension in these regions and excessive smoking in the U.S. Asia and South America exhibit minimal incidence of renal cell carcinoma. (sbwire.com)
  • The age-adjusted incidence of renal cell carcinoma has been rising by 3 percent per year. (reportlinker.com)
  • This review provides an overview of the incidence of renal cell carcinoma (RCC) and a summary of the most commonly associated risk factors. (dovepress.com)
  • An increased incidence of RCC has been associated with end-stage renal disease and with acquired cystic kidney disease. (atlasgeneticsoncology.org)
  • Brain, spinal cord, and lung are prevalent sites of metastasis from primary renal cell carcinoma (2). (isciii.es)
  • Patients with primary renal cell carcinoma. (knowcancer.com)
  • The vast majority of patients with renal cell carcinoma developing gastric metastases showed symptoms as microcytic anaemia or upper gastrointestinal haemorrhage, dyspepsia or abdominal pain, similar to those patients with primary gastric tumours. (isciii.es)
  • Moreover, there are many pipeline drugs in various phases of clinical trials, which will fuel the growth of renal cell carcinoma drugs market. (medindia.net)
  • However, CRCC is frequently misdiagnosed as a benign renal cyst because it shares similar clinical manifestations and imaging characteristics. (medscape.com)
  • To date, no effective therapy is available for patients with advanced PRCC ( 11 ), and patients with PRCC may be excluded from clinical trials that are usually designed for the more common clear cell RCC. (aacrjournals.org)
  • Despite the improvement in renal cell carcinoma (RCC) diagnosis and management observed during the last 2 decades, RCC remains one of the most lethal urological malignancies. (urotoday.com)
  • According to the National Organization of Rare Disorders (NORD), renal cell carcinoma accounts for approximately 30,000 new cases of kidney malignancies per year in the United States. (researchandmarkets.com)
  • Histological examination evidenced morphological aspects characteristic to the mixt renal carcinoma. (scielo.br)
  • In a benign tumour the cells do not spread to other parts of the body and so are not cancerous. (naturalcures.com)
  • In 25-30% of cases, renal cell carcinomas are found incidentally in asymptomatic patients. (medscape.com)
  • The therapeutic potential of HIF-2 antagonism in renal cell carcinoma. (nih.gov)
  • Renal cell carcinoma, the most common form of the disease, is often diagnosed when it has already spread to other organs - and until recently, patients had few therapeutic options. (mskcc.org)
  • Renal cell carcinoma is rarely detected in the early stages of disease, since there are often no obvious symptoms until the disease has reached an advanced stage. (news-medical.net)
  • The symptoms of renal cell carcinoma can mimic those for other conditions so it is important to see your physician for a proper diagnosis. (cancertutor.com)
  • It is now known that this classic triad of symptoms only occurs in 10-15% of cases, and is usually indicative that the renal cell carcinoma (RCC) is in an advanced stage. (wikipedia.org)
  • Laboratory findings were increased white blood cells count, as well as elevations of serum C-reactive protein and lactic dehydrogenase (LDH), which was consisted of subtype 1 and 2 (Figure 1 ). (hindawi.com)
  • Accounting for 25% of PRCCs, type 2 PRCC is the pathological subtype that is most commonly associated with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. (wikipedia.org)